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Misfolded α-synuclein aggregates into amyloid fibrils. These fibrils are the principal 
component of Lewy Bodies, intracellular inclusions that are one of the pathological 
hallmarks of Parkinson’s disease. Despite the accumulation of α-synuclein fibrils being 
a marker for disease, their contribution to Lewy Body pathology and disease 
progression is not well understood. Exogenous α-synuclein fibrils are able to seed the 
formation of Lewy Bodies by promoting the aggregation of endogenous α-synuclein. 
Using proteomics, this project aimed to determine how the presence of α-synuclein 
fibrils affected the cellular proteome in the early stages of Lewy Body formation using 
SH-SY5Y cells that overexpress GFP-α-synuclein as a model. Tandem mass tagging 
quantitative proteomics identified 11 proteins with significantly altered levels resulting 
from exposure of the SH-SY5Y GFP-α-synuclein cell line to α-synuclein fibrils for 1 and 
5 days. Among these proteins were members of the collagen and microtubule-
associated protein families, they have roles in a plethora of cellular processes including 
signalling, structural maintenance and intracellular organisation. Alterations to their 
function could cause cellular dysfunction, which could contribute to the pathogenic 
conditions seen in Lewy Body formation and Parkinson’s disease. This highlights the 
importance of proteomics in further understanding the contribution that α-synuclein has 
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Parkinson’s disease (PD) is the second most common neurological disorder after 
Alzheimer’s disease (AD), affecting over ten million people worldwide [1]. This age-
related degenerative disease affects both the central and peripheral nervous systems 
and is characterised by the loss of dopaminergic neurons in the substantia nigra pars 
compacta (SN), the region of the brain responsible for coordination of body movement 
[2]. Gradual loss of dopaminergic neurons in this region results in the decline of motor 
skills, cognitive function and other processes with clinical symptoms including 
bradykinesia, tremor, anxiety and sometimes dementia [3]. In combination with the loss 
of dopaminergic neurons, reduced levels of dopamine is responsible for most of the 
clinical symptoms exhibited by patients with PD. The current treatments available for PD 
only provide symptomatic release. The first of these is levodopa, when administered it is 
absorbed by neurons and converted into dopamine [4]. Dopamine agonists can also be 
administered as a substitute for dopamine [5]. The final treatment is Monoamine oxidase-
B (MAO-B) inhibitors. MAO-B inhibitors prevent the activity of the enzyme MAO-B which 
acts to break down dopamine, this in turn results in an increase in dopamine levels [5]. 
As these treatments only provide symptomatic release, they do not inhibit the 
progression of the disease and as a result, become less effective over time with the 
progressive loss of dopaminergic neurons.  
The main histopathological hallmark of PD, after the loss of dopaminergic neurons, is 
the presence of the proteinaceous cytoplasmic inclusions known as Lewy Bodies (LBs) 
found in the cytoplasm and Lewy Neurites (LNs) found in the neurites of neurons 
surviving in the SN region. These are proteinaceous cytoplasmic inclusions which mainly 










LBs were first discovered over 100 years ago with the presence of α-synuclein first 
reported 23 years ago [7, 8]. Since their discovery, the presence of filaments in LBs has 
been one of the most consistent observations. Despite the filaments initially thought to 
be neurofilaments, the discovery of α-synuclein in LBs shifted interest from 
understanding the complexity of LBs to understanding the role of α-synuclein in LB 
formation [9].  
Since the discovery of α-synuclein in LBs, the major change in approaches used to study 
LBs and Lewy pathology was the development of a wider range of antibodies against α-
synuclein and other proteins present in LBs. These antibodies have allowed for 
increased profiling of LB composition, greater appreciation of Lewy pathologies and 








FIGURE 1. Substantia nigra from normal and Parkinson’s disease brains. A) Dopaminergic neurons 
are lost in the substantia nigra during PD. This is shown by the arrows in the normal and PD images which 
indicate a lack of pigmentation. B) Magnified images of substantia nigra tissue clearly show the loss of 
pigmented neurons during PD. C) Magnified image of a Lewy Body in the substantia nigra present in PD. 






Although LBs are the second major histopathological hallmark of PD, LBs and 
pathological α-synuclein aggregates are present in several diseases collectively termed 
synucleinopathies. Different clinical and pathological phenotypes are seen between 
synucleinopathies, even though they are caused by aggregation of the same protein. In 
PD and dementia with Lewy bodies (DLB), α-synuclein aggregates in neuronal cells 
forming LBs, whereas in multiple system atrophy (MSA), α-synuclein aggregates in 
oligodendrocytes forming glial cytoplasmic inclusions (GCIs). All three of these 
synucleinopathies are rarely familial and in the case of MSA, mutations in α-synuclein 
have not been observed [11]. 
The occurrence of GCIs in oligodendrocytes and not neurons highlights the role that the 
intracellular environment plays in generating different strains of α-synuclein aggregates 
[12]. These differences suggest that different strains are responsible for the distinct 
pathology between synucleinopathies [13]. Expression of α-synuclein in 
oligodendrocytes reproduces the MSA phenotype, however, α-synuclein is not 
expressed by oligodendrocytes under physiological conditions and is not upregulated 
during MSA [14]. Regardless of the source, α-synuclein accumulates in MSA, suggesting 
a process distinct from Lewy pathology.  
DLB more closely resembles PD in terms of LB pathology, however, DLB predominantly 
presents dementia whereas, PD presents motor symptoms [15]. Different seeding 
kinetics of α-synuclein in patients with DLB were observed when compared to PD. It was 
shown that in DLB-seeded reactions the generation of a proteinase K-resistant fibrillary 
α-synuclein occurred, whereas in PD, wild-type (WT) α-synuclein was not converted by 
seeds. The differences in kinetics and the products produced between DLB and PD 
indicate an existence of α-synuclein strains [16].  
α-synuclein also deposits in other neurodegenerative disorders. Lewy pathology is 
observed in 60% of AD cases but it is mostly restricted to the amygdala compared to PD 
or DLB [17]. 
 
4.2. The SNCA gene 
In the 1990s, mutations in the SNCA gene were discovered to be associated with early-
onset familial forms of PD [18]. The SNCA gene encodes the protein α-synuclein and is 
located on chromosome 4q22.1. Mutations in SNCA are responsible for both familial and 
a small percentage of sporadic forms of the disease with seven dominant mutations 
linked to familial PD; A53T, A53E, A53V, A30P, E46K, G51D and H50Q [13, 19]. Of the 




most frequent with it seen in a total of 12 families. The other two missense mutations, 
A30P and E46K have each been identified in one family each [18]. Penetrance of the 
missense mutations appears high with the A53T mutation suggested to be around 85% 
[19]. It is believed that the missense SNCA mutations cause PD through a toxic gain of 
function and presence of α-synuclein aggregates within LBs may be an attempt to 
remove damaged α-synuclein [20].  
While all these single amino acid mutations lead to early onset of the disease, they have 
different effects on α-synuclein aggregation rate. G51D, A30P and A53E slow the rate of 
fibril formation while E46K, H50Q and A53T lead to an increase in fibril formation rate 
[19]. The dominant mutations also affect the association of α-synuclein with phospholipid 
membranes. G51D, A30P and A53E result in reduced phospholipid binding while E46K 
and A53T have been shown to increase phospholipid binding [19]. 
Due to the presence of α-synuclein aggregates within LBs and the range of effects the 
seven mutations cause, extensive work has been conducted to elucidate the role of α-
synuclein in PD, beginning with understanding the structure of the protein. 
 
4.3. Structure of α-synuclein 
α-synuclein is comprised of 140 amino acids and is expressed at high levels in the brain, 
predominantly localised to the pre-synapse of neurons where it is believed to be involved 
in several processes [20]. The soluble form of α-synuclein is natively unstructured but it 
adopts a partial α-helix upon binding to membranes [21]. The protein contains three 
major regions: an amphipathic N-terminal region (1-60), a non-amyloid component 
(NAC) (61-95) and a C-terminal region (96-140). The N-terminal region has seven highly 
conserved 11 amino-acid repeat sequences forming an amphipathic α-helix which 
enables the protein to bind with membranes [21]. The NAC region is a hydrophobic 
region which is amyloidogenic and responsible for protein aggregation [22]. The C-
terminal region is polar and contains majority of the protein’s post-translational 






4.4. Physiological role of α-synuclein 
α-synuclein is widely expressed by neural populations within both the central and 
peripheral nervous systems, predominantly located at nerve terminals [25]. Under 
physiological conditions, monomeric α-synuclein is natively unfolded. In the absence of 
a transmembrane domain or a lipid anchor, it is unclear how α-synuclein localises to the 
nerve terminal, however, this is proposed to be dependent on its amphipathic N-
terminus. The N-terminus contains seven 11 residue repeats which have been 
suggested to adopt an α-helix conformation, essential for binding to curved membranes 
[26]. Binding to the phospholipid headgroups of the membrane requires basic residues 
such as lysine found on opposite sides of the helix (Fig. 3).  
Although the interaction between α-synuclein and the lipid membrane is weak, α-
synuclein is known to be highly localised at the synapses where it interacts with synaptic 










FIGURE 2. Structure of the α-synuclein protein. The N-terminal domain (pink) is composed of KTKEGV 
repeats. Missense mutations associated with familial PD have been found in this region. The central non-
amyloid component (NAC) domain (blue) is responsible for α-synuclein aggregation. The C-terminal 






The release of neurotransmitters at nerve terminals is a highly regulated process and 
relies upon the formation of the SNARE complex. The SNARE complex is formed of four 
α-helices, one from each synaptobrevin-II, syntaxin-1A and two from SNAP-25 [27]. 
Syntaxin-1A is located on the vesicle membrane while synaptobrevin-II and SNAP-25 
are located on the plasma membrane [28]. Vesicle fusion during presynaptic exocytosis 
is coupled to the Ca2+ receptor synaptotagmin. Ca2+ binding to synaptotagmin allows for 
formation of the SNARE complex at the plasma membrane and subsequent release of 
neurotransmitters into the synaptic cleft [29]. α-synuclein has been shown to promote 
assembly of the SNARE complex by binding to synaptobrevin-II via its C-terminus [30, 
31]. This function of α-synuclein is important with increased synaptic activity and ageing, 
therefore maintenance of the SNARE complex is essential. Aggregation of α-synuclein 
has been suggested to impair the function of the SNARE complex. Aggregated forms of 
α-synuclein could bind to multiple synaptobrevin-II preventing its interaction with the 
other members of the SNARE complex, resulting in a reduction of neurotransmitter 
release [31], (Fig. 4). Loss of α-synuclein function, for example, by sequestration of α-
synuclein in LBs would have a similar effect; resulting in a loss of neuronal function and 
possible contributions to synucleinopathies [30]. 
 
 
FIGURE 3. The proposed α-helical formation of the N-terminus of α-synuclein upon membrane 
binding. The N-terminus of α-synuclein contains seven 11 residue repeats. The consensus sequence of 
repeats is given on the left. The height of the single letter amino acid code indicates the probability of 
finding that residue in the repeats. The helical wheel is given on the right. The numbers around the wheel 
represent the position of a residue within a repeat, while the distance from the centre represents which of 
the seven repeats the residues are located in. Blue indicates basic, red acidic, purple polar uncharged and 






α-synuclein might also act as a fatty acid binding protein, promoting polyunsaturated fatty 
acid uptake into cells, via clathrin-dependent endocytosis [32]. This was supported by 
analysis of α-synuclein knockout mice which presented a reduction in brain cardiolipin 
[33]. Changes in fatty acid uptake and metabolism also supported the role of α-synuclein 
as a fatty acid binding protein. The uptake of palmitic acid in the brain of α-synuclein 
gene-ablated mice decreased as well as its incorporation into the brain acyl-CoA pool 
[34, 35]. Although uptake of docosahexaenoic acid was not affected in the same model, 
incorporation into the brain acyl-CoA pool was elevated 1.5-fold [34, 35]. This showed 
that α-synuclein has effects on the uptake and metabolism of fatty acids.  
It has been reported that α-synuclein interacts with a number of proteins that may 
regulate its activity. Tubulin appears to interact with aggregated α-synuclein, resulting in 
microtubule dysfunction. Overexpression of α-synuclein in SH-SY5Y cells led to 
disruption of the microtubules network and trafficking, this was associated with 
mislocalisation of tubulin to α-synuclein aggregates in degenerating neurites [36]. 
Recently, the small GTPase Rab3a has been suggested to regulate the membrane 
association of α-synuclein in a GTP-dependent manner [37]. Rab3a is involved in the 
docking of synaptic vesicles to the membrane during neurotransmitter release 
suggesting a relationship between this process and the involvement of α-synuclein in the 
synaptic-vesicle cycle, the extent of which is unclear at present.  
 
FIGURE 4. Proposed mechanistic model for enhancement and inhibition of SNARE-dependent 
vesicle fusion by α-synuclein. In the enhancement model, monomeric α-synuclein acts as a cross-bridge 
to facilitate vesicle docking to the phospholipid bilayer. The inhibition model involves aggregated α-
synuclein interacting and clustering with several synaptobrevin-II, thus preventing synaptobrevin-II from 




4.4.1. Amyloid fibril formation and structure 
In LBs, α-synuclein is present in the form of amyloid fibrils. The aggregation of α-
synuclein into amyloid fibrils consists of three phases. First is the lag phase, this is the 
rate-limiting step where oligomers form an aggregation-competent nucleus [38]. Second 
is the elongation phase where the nucleus is converted into protofilaments that 
aggregate into fibrils. Within the protofilaments, α-synuclein is organised into a cross-β 
structure whereby β-strands are arranged into β-sheets perpendicular to the fibril axis 
[39]. The cross-β structure is a common characteristic among amyloids. The final stage 
of aggregation is the stationary phase at which point the majority of the soluble α-
synuclein has been converted into fibrils [38].  
Recently, atomic resolution structures of α-synuclein have been elucidated using solid 
state NMR [40] and cryogenic electron microscopy (cryoEM) on reconstituted α-
synuclein fibrils [41, 42]. The deduced Greek-key conformation showed that each α-
synuclein subunit in the fibril adopts a β-sheet conformation with hydrogen bonding 
between adjacent α-synuclein subunits. The β-sheet rich core is located between 
residues 42-102 comprising of a hydrophobic region that forms right-angled spirals and 
is largely comprised of Ala/Val residues [41, 42]. The outer surface of the fibril is mostly 
hydrophilic [41, 42], (Fig. 5A). The 3D map of α-synuclein fibrils shows two protofilaments 
interacting with each other via two β-sheets from each protofilament forming hydrophobic 
zipper geometry, resulting in the two polymorphs; the rod conformation (polymorph 1a) 
and the twisted conformation (polymorph 1b), [41, 42] . 
The rod fibrils are 10nm wide composing of two adjacent protofilaments that form a 
hydrophobic zipper with a potential salt bridge between E57 and H50 of the adjacent 
subunits [19]. The twister fibrils share the kernel structure that comprises the dimeric 
protofilament but differs in the interface configuration. The helical pitch of the twister 
structure is 460 Å compared to 920 Å for the rods (Fig. 5B). Unlike the Greek-key fold 
and pre-NAC interface (residues 47-56) seen in the rod fibrils, the subunits of the twister 






It is known that familial mutations of PD affect the aggregation of oligomers during the 
lag phase, which is the rate-limiting step of fibril formation, these mutations also alter 
fibrillation kinetics [38]. Sahay et al. (2015) investigated the effects of familial PD-
mutations A53T, E46K and A30P to alter the long-range intramolecular interactions, 
structural compactness and conformational equilibrium of α-synuclein [43]. Although the 
overall secondary structure was the same for these mutant proteins, aggregation studies 
showed that A30P had slower fibril formation compared to WT α-synuclein while E46K 
and A53T had a faster fibril formation rate. Despite the differences in fibril formation, all 
three mutants had an increased propensity to form oligomers [43]. In WT α-synuclein 
there is a salt bridge between E46 and K80 side chains, which is compromised in the 
E46K mutant. Electrostatic repulsion destabilised the Greek-key conformation leading to 
increased oligomerisation compared to WT α-synuclein [44]. The three mutants 
decreased solvent exposure and altered the rigidity of the C-terminus. All three mutations 




FIGURE 5. The structure of an α-synuclein fibril. A) Structure of a single layer within an α-synuclein fibril 
displaying formation of the Greek-key topology. The early onset mutations are highlighted in pink as well as 
the three electrostatic interactions which are perturbed in early onset PD. B) 3D model of the rod (top) and 
twister (bottom) fibril polymorphs, annotated with their helical pitches. C) The interface of the rod fibril is 
composed of residues within the preNAC region (blue, residues 47-56) in which most early-onset PD 
mutations are located (cyan). The twister fibril interface is composed of residues within the NAC core region 




rigidity compared to WT. This indicated that the mutations differentially affected 
conformational changes in the NAC, N- and C- terminal regions during α-synuclein 
aggregation [43].  
Li et al. (2018) investigated the effect that several familial mutations located in the pre-
NAC region (E46K, H50Q, G51D, A53E, A53T and A53V), had on the rod and twister 
polymorphs. They proposed that these mutations would disfavour the fibril core of the 
rod structure but not the twister, due to the mutations being contained in the interface of 
the rod fibrils and not twister fibrils. These mutations were therefore likely to result in a 
decrease of the rod polymorph. It was suggested that changes in the type of fibril 
polymorphs present may alter their activity, for example, their capability to bind to 
membranes and as such, underlie the differences in phenotype presented by patients 
with familial PD, concluding that α-synuclein fibril polymorphs may contribute to the 
pathogenicity of α-synucleinopathies [42]. 
Two additional polymorphic structures of α-synuclein have been solved by cryo-EM, 
named polymorph 2a and 2b [45]. Like the rod (polymorph 1a) and twister polymorph 
(polymorph 1b), these are composed of two protofilaments, 10nm in diameter but they 
display different arrangements. In the absence of a steric zipper, salt bridges are 
observed between K45-E57 (polymorph 2a) and K45-E46 (polymorph 2b). Unlike the 
familial mutations in polymorphs 1a/b which are within a steric zipper structure, for the 
polymorphs 2a/b they are contained in a hydrophobic cleft [45], (Fig. 6).  
 
FIGURE 6. Schematic representations of the four currently characterised α-synuclein polymorphs. 
Type 1 polymorphs have steric zipper geometry while the type 2 polymorphs are characterised by a 
hydrophobic cleft stabilised by intermolecular salt bridges and additional interactions between the NAC 
region and N-terminus, The N-terminus is shown in blue, NAC region in red and the C-terminus in yellow. 




It has been largely accepted that the native state of α-synuclein changes under 
pathological conditions, whereby, it misfolds into a partially folded soluble oligomeric 
state that later forms insoluble fibrils [46]. Once taken up by cells it is unknown how 
pathological α-synuclein species initiate recruitment of intracellular α-synuclein. The 
prevailing hypothesis is that internalized α-synuclein escapes from the endocytic 
pathway allowing it to contact the intracellular pool of monomeric α-synuclein [47]. It has 
been shown that upon treating primary neurons with preformed fibrils, a small amount 
within the cells co-localises with endogenous α-synuclein, suggesting that direct 
conversion and recruitment of monomeric α-synuclein may be enough to initiate α-
synuclein pathology [48]. 
Several studies have suggested that α-synuclein fibrils are not the only species 
responsible for the pathogenic events seen in synucleinopathies, in fact, it has been 
proposed that oligomers of α-synuclein may contribute. Work in primary rat neurons 
showed the formation of two types of oligomers which form during α-synuclein 
aggregation [49]. Oligomers formed during the early stages of aggregation were shown 
to be non-toxic but they can later convert into stable protein kinase resistant oligomers 
which are toxic. Further to this, incubation of primary neurons with fibrils in the absence 
of monomer release resulted in the release of soluble oligomeric species which 
resembled the toxic oligomers formed during aggregation [49].  
Upon injection of α-synuclein oligomer variants into the rat SN, a decrease in 
dopaminergic neurons was observed most prominently for E35K and E57K α-synuclein 
[50]. These two variants have a decreased tendency to form fibrils and were therefore 
considered as oligomer-promoting variants. Upon addition of the E57K variant to an 
immortalized human cell line, high-toxicity was induced. An increase in Ca2+ influx and a 
decrease in cell viability, indicative of membrane and cellular dysfunction was observed 
[50]. Overall, this work indicates a role of α-synuclein oligomers in the pathogenic events 
of PD.  
 
4.5. Pathological role of α-synuclein 
The spread of α-synuclein pathology through different regions of the brain occurs over 
time. First proposed by Braak et al. (2003), initial appearance of α-synuclein aggregation 
occurred in the dorsal motor nucleus of the vagal nerve (DMV) and olfactory bulb before 





However, the stages initially proposed to describe the progression only fit half of all α-
synucleinopathy cases [52]. Later, a future study evaluated a number of α-
synucleinopathies and suggested a revised staging system which saw an initial stage 1 
where the olfactory bulb and DMV was affected followed by a divergence into stage 2a 
(brainstem predominant) or stage 2b (limbic predominant). The two pathways then 
converge into stage 3 where both brainstem and limbic areas were affected. At this point, 
the motor manifestations of PD generally appear. During stage 4, α-synuclein deposits 
are seen in the temporal cortex and in the neocortex by stage 5, likely contributing to the 
cognitive defects observed in advanced PD [53, 54]. 
With the appearance of α-synuclein inclusions in the olfactory bulb and DMV prior to the 
onset of clinical symptoms in PD, the ‘body-first’ hypothesis was proposed [51]. This 
hypothesis suggested that the pathology may occur at peripheral sites before travelling 
to the central nervous system inducing the disorder that is recognised as PD. The 
connection between gastro-intestinal (GI) dysfunction and PD is well established, with 
constipation being one of the non-motor symptoms of the disease, this supports the 
‘body-first’ hypothesis [52]. Recent work in a bacterial artificial chromosome (BAC) rat 
model supported the ‘body-first’ hypothesis, providing the first animal model to show 
evidence of α-synuclein propagation to the heart and bi-directional propagation from the 
duodenum to brainstem to stomach. This also provided an explanation for the cardiac 
denervation which can occur in the prodromal phase of PD [55].  
The spread of α-synuclein aggregates between individual neurons is said to occur in a 
‘prion-like’ manner. α-synuclein aggregates generated in one neuron are transferred to 
FIGURE 7. Schematic summarising the staging of Lewy pathology according to the Braak model. 
The disease process commences in the lower brainstem in the dorsal motor nucleus of the vagus nerve 
(DMV), as well as anterior olfactory structures. The disease then ascends rostrally from the DMV through 
susceptible regions of the medulla, pontine tegmentum, midbrain, and basal forebrain, eventually reaching 





a neighbouring neuron via the synapse, acting as a template for misfolding of α-synuclein 
in the recipient neurons [53, 54, 56], (Fig. 8). 
 
 
Unlike prions, pathological α-synuclein shows no evidence of being infectious to other 
organisms therefore, the transmission is said to be ‘prion-like’ as it is transmissible 
between cells in a host not between hosts as is the case for prion diseases [57]. The 
prion-like propagation of α-synuclein was first suggested when neural transplants 
injected into the striatum of PD patients more than 10 years prior to death were shown 
to contain LBs at autopsy [58, 59]. The same effect was seen in animal models. Through 
transplantation of cortical neuronal stem cells into the hippocampus of mice 
overexpressing human α-synuclein, it was shown that the human α-synuclein could 
transfer to the transplanted cells [60].  
It was also important to show that α-synuclein could induce prion-like propagation in the 
absence of diseased material. Truncated mouse α-synuclein, lacking the C-terminus, 
was injected into the brains of WT mice and shown to cause time-dependent protein 
spreading and aggregation [61]. Although occurring at a slower rate, the same capacity 
to inflict synucleinopathy occurred for human α-synuclein aggregates [62]. It has been 
shown that recombinant α-synuclein fibrils can enter neurons by endocytosis and seed 
the formation of aggregates composed entirely of endogenous α-synuclein resembling 
early LB pathology [63]. This was demonstrated by intracerebral injection of α-synuclein 
fibrils into WT mouse brains. α-synuclein pathology was induced, the spread of which 
depended on the injection sites and seeding capabilities of the fibrils [64]. 
FIGURE 8. Schematic of the ‘prion-like’ spread of α-synuclein aggregates. Seeding-potent 
aggregates spreading from cell to cell. They enter the cell after binding to their receptor (1). After 
internalization, aggregates spread over the cell and transmit to second order neurons via exosomes (2) 





4.5.1. Release of α-synuclein aggregates 
For the spread of α-synuclein to occur from one cell to the next, α-synuclein must be 
released. Release of monomeric α-synuclein appears to be a regulated event with very 
little α-synuclein detected in media and cerebrospinal fluid [65]. Cell culture studies have 
found that stress on the proteostasis machinery can result in α-synuclein release. While 
this may benefit the cell initially, this may be the primary mechanism that leads to the 
transmission of pathological α-synuclein [52]. 
The co-chaperone DNAJC5 plays a role in secretion of aggregated α-synuclein via the 
process of misfolding-associated protein secretion [66]. Experiments in immortalised 
cells saw aggregates being shuttled from the cytosol to the cell surface in a DNAJC5-
dependent manner. The aggregates were then endocytosed by other cells and degraded 
in the lysosome [66].  
α-synuclein release has been shown to involve exosomes usually targeted for 
degradation by the lysosomes [67]. Exosomes are the luminal membranes of 
multivesicular bodies (MVBs). MVBs form through invagination of endosomal 
membranes, trapping cytosolic proteins such as α-synuclein in the process. With α-
synuclein degradation occurring via the lysosomes, it is plausible that α-synuclein on the 
pathway to the lysosomes could be susceptible to release in this manner. This release 
appears to occur with calcium-dependent regulation which may be relevant for the 
spread of α-synuclein pathogenesis along synaptically connected pathways [68].  
Furthermore, the use of quantitative fluorescence microscopy has shown that once 
lysosomes become overloaded with α-synuclein aggregates, fibrils can be transferred 
from one cell to another inside lysosomal vesicles via tunnelling nanotubes [69].  
 
4.6. Cellular impact of α-synuclein aggregation 
4.6.1. Lysosomes  
Lysosomal integrity is impaired with age and elevated release of internalised α-synuclein 
from damaged lysosomes has been proposed as one of the mechanisms by which age 
could lead to pathogenic α-synuclein accumulation [70]. Lysosomes are single-
membrane organelles that aid in the maintenance of cellular metabolism [71], degrading 
and recycling a variety of molecules and organelles into their constituent components 
[72]. Failure of lysosomes leads to the accumulation of dysfunctional proteins and 
organelles. There are several routes for macromolecules to reach the lysosome. Material 
from outside the cell is taken up by clathrin-mediated endocytosis, these vesicles then 
fuse to endosomes which mature into late endosomes fusing with the lysosomes for 




Endosomal/lysosomal function has been shown to act as a barrier to the induction of α-
synuclein pathology. However, when compromised it may lower the threshold for 
pathology transmission. It was suggested that exogenous α-synuclein fibrils may disrupt 
this function leading to aggregation within the cytoplasm [74].  
The inability of lysosomes to digest and degrade molecules leads to lysosomal storage 
disorders (LSDs). Individually each type of LSD is rare but collectively their rate of 
incidence is about 1 in 7000 live births which is relatively high [75]. The central nervous 
system (CNS) and peripheral nervous system (PNS) are particularly vulnerable to 
storage deficits due to their high content of sphingolipids and ceramide. Intact functioning 
of lysosomes is crucial for neurons as they do not replicate in adult life and have a large 
degree of oxidative metabolism [76]. 
Lysosomal impairment and its role in PD is supported by genetic associations between 
PD and Gaucher’s disease (GD), the most common LSD. GD results from a homozygous 
mutation in the glucosidase beta acid (GBA) gene, encoding the lysosomal hydrolase 
glucocerebrosidase (GCase), [77]. GCase converts glucosylceramide (GC) into glucose 
and ceramide, failure of this process leads to impairment of lysosomes and an 
accumulation of lipids [78]. Although GD is an autosomal recessive disorder, the 
inheritance of parkinsonism associated with rare GBA mutations does not follow 
Mendelian genetics, increasing the risk of PD in a heterozygous state [79]. Due to this, 
both gain-of function and loss-of function theories have been proposed [78]. As most 
mutant alleles result in misfolded GCase, this supports a gain of function role for these 
mutations. Abnormal conformations could contribute to increased α-synuclein 
aggregation resulting in the development of parkinsonism, on the other hand, it could 
lead to lysosomal dysfunction. Parkinsonism could also occur because of loss of function 
of GCase. The misfolded protein could be degraded leading to enzyme deficiency and 
substrate accumulation [80]. 
Accumulation of GC, resulting from a reduction in GCase activity, may promote α-
synuclein aggregation through the disruption of its levels within the lysosomes. In support 
of this, when human dopaminergic neurons were treated with the GCase inhibitor 
conduritol B epoxide (CBE), GCase activity was reduced and α-synuclein levels were 
increased [81]. Moreover, high concentrations of GC resulted in increased formation of 
α-synuclein fibrils in both human induced pluripotent stem cells (iPSCs) cells and primary 
neurons [82]. Knockdown of GBA1 causes down regulation of autophagy by inactivation 
of protein phosphatase 2 (PP2A) in both SK-N-SH neuroblastoma cells and primary rat 
cortical neurons. The inhibition of the autophagic pathway in turn resulted in increased 
accumulation of α-synuclein [83].  Disruption of the lysosome reformation process in SH-




As well as reduced GCase activity leading to an increase in α-synuclein, increased levels 
of α-synuclein have been shown to decrease GCase activity. This may occur by α-
synuclein promoting the impairment of GCase trafficking. In support of this, in primary 
cortical neurons, the level of GCase retained in the ER can be reduced by lowering α-
synuclein levels and conversely, overexpression of α-synuclein can cause accumulation 
of GCase in the ER [82]. Upon interaction with α-synuclein, GCase moves from its usual 
position at the membrane with its active site positioned further from the lipid bilayer. The 
activity of GCase is dependent on its interaction with membrane phospholipids therefore 
this interaction my also explain the reduction in GCase activity [85]. As reduced GCase 
activity can increase α-synuclein levels these mechanisms may be part of a positive 
feedback loop whereby an increase in α-synuclein reduces GCase activity resulting in a 
continued increase of α-synuclein. 
 
4.6.2. Autophagy 
The major pathways for disposal of α-synuclein in the cells are macroautophagy, 
chaperone-mediated autophagy (CMA) and proteasomal degradation. Macroautophagy 
describes the engulfment of cytoplasm by phagophores which expand into 
autophagosomes, mature autophagosomes are then targeted by the lysosomes for 
degradation [86]. CMA involves direct translocation of unfolded proteins across the 
lysosome membrane. Chaperone proteins mediate this process by binding to cytosolic 
substrates which enter the lysosome through interaction with receptors on the lysosomal 
membrane [87]. 
In its native form α-synuclein is degraded by CMA [88]. α-synuclein contains a KFERQ 
CMA recognition motif. This pentapeptide motif is recognised by the chaperone protein 
Hsc70 allowing the two to bind. At the lysosomal membrane α-synuclein then binds to 
the lysosomal-associated membrane protein type 2A (LAMP-2A). With the aid of the 
Hsc70, this receptor transports α-synuclein into the lysosome for degradation. 
Decreased levels of LAMP-2A and Hsc70 have been associated with α-synuclein 
aggregation in the early stages of PD [89]. 
Impairment of the autophagy-lysosomal pathway (ALP) was shown in PD brain samples. 
The microtubules-associated protein 1A/1B-light chain 3 (LC3), an autophagosomal 
marker, was present within LBs of PD brains with up to 80% nigral LB being positive for 
LC3 [90]. Impairment of macroautophagy can lead to an increase in α-synuclein 
secretion by several pathways. Knockdown of the macro autophagy component Atg5 led 
to an increase in exosomal α-synuclein aggregates [91]. Also, extracellular vesicles 




taken up by other neurons and trafficked through axons [92]. These results suggest that 
vesicular transport may be one of the ways in which synucleinopathies spread [47]. 
Autophagic defects were observed upon silencing of LAMP-2A in the dopaminergic cells 
of a rat model. Accumulation of autophagic vacuoles were surrounded by α-synuclein 
puncta positive for ubiquitin [93]. The expression of microRNA (miRNA) targeting LAMP-
2A in SH-SY5Y cells led to α-synuclein accumulation after defects in CMA [94]. These 
miRNAs, miR224 and miR373, are upregulated in the SN of PD patients suggesting that 
CMA-mediated α-synuclein clearance defects in pathological conditions could contribute 
to their accumulation.  
While CMA acts to regulate the level of α-synuclein and its aggregation within the 
cytoplasm, α-synuclein can in turn disrupt CMA, altering the turnover of other CMA-
dependent proteins. The different mutant forms of α-synuclein vary in the way they affect 
its ability to be degraded, therefore having different levels of toxicity. In cell culture the 
A53T and A30P mutants bind strongly to LAMP-2A compared to WT but cannot be 
internalised by the lysosome, they act as receptor inhibitors preventing the binding of 
other CMA targets [95]. This results in a compensatory toxic gain-of-function activation 
of the macroautophagy process to counteract the CMA blockade [96]. These data 
suggest that α-synuclein is a substrate for macroautophagy and CMA with their 
impairment contributing to the accumulation and aggregation of α-synuclein in 
synucleinopathies [97], (Fig. 9). 
With the relationship of α-synuclein and the ALP in the accumulation and aggregation of 
α-synuclein being well established, the role of α-synuclein in the disruption of the ALP is 
known to contribute to α-synuclein pathology  through numerous cellular alterations [97]. 
Overexpression of WT α-synuclein resulted in inhibition of autophagy through 
impairment of autophagosome formation. This was suggested to involve a decrease in 
α-synuclein induced Rab1 activity, which disrupts the localisation of the Atg9 protein 
involved in autophagosome formation [98]. When α-synuclein transfers from cell to cell, 
autophagic impairment was observed in the recipient cell with accumulation of deficient 
lysosomes that had become enlarged, increasing pathology [99].  
In PC12 cells, overexpression of mutated A53T α-synuclein decreased autophagic 
activity. When A53T α-synuclein lacking the CMA recognition motif was then expressed, 
it did not alter autophagic activity. This was due to upregulation of macro autophagy, 
compensating for the deficit of CMA, however, this resulted in detrimental conditions 
which contributed to cell death [100]. The disruption of CMA by A53T α-synuclein also 
caused abnormal accumulation of the myocyte enhancer factor 2 (MEF2D) in the cytosol. 
This prevented it from binding to DNA and therefore its role in gene regulation of cellular 




In combination these data highlight how α-synuclein disrupts the ALP machinery, 
contributing to cellular dyshomeostasis and neuronal death as well as exacerbating the 
pathological synucleinopathy by a dual-loop effect (Fig. 9).  
 
 
4.6.3. Mitochondria  
Mitochondria have been closely linked to the pathogenesis of PD with a reduction of 
complex I activity seen in post mortem brain samples of PD patients [102]. This reduction 
is also seen in transgenic mice overexpressing WT α-synuclein or A53T α-synuclein 
[103]. Both normal and abnormal α-synuclein have been shown to interact with 
mitochondria and this binding appears enriched in PD brain samples [104]. The 
translocation of α-synuclein into the inner mitochondrial membrane structures is not fully 
understood, but Tom40 a component of the Translocase of outer mitochondrial (TOM) 
complex is believed to be involved [104]. Evidence of this was shown by decreased 
levels of Tom40 in the brains of PD patients [105]. Interactions with translocases of the 
inner membrane, TIM16 and 44 have also been seen with aggregated α-synuclein 
FIGURE 9. Dual-loop between autophagy lysosomal pathway and α-synuclein. In physiological 
conditions α-synuclein is degraded by chaperone mediated autophagy and macroautophagy, with low 
exosomal release of α-synuclein. In pathological conditions, the clearance of α-synuclein is decreased due 
to impairment of autophagy. The exosomal pathway is increased to compensate for the loss of autophagy 
mechanisms resulting in increased release and cell-to-cell propagation of the protein. Reciprocally, 
accumulated α-synuclein induces cell toxicity by autophagy impairment forcing the cell into a cycle of 





favouring TIM44 [106]. These interactions allow for the possibility that α-synuclein can 
be translocated into the mitochondrial matrix. 
DJ-1 is a multi-functional protein with its predominant role in the protection of cells 
against oxidative stress [107]. Mutations in the PARK7 gene, encoding DJ-1, account for 
0.4% of early onset PD cases, occurring in an autosomal recessive manner [108]. DJ-1 
activity is regulated by oxidative modification of its C106 residue. Upon exposure to 
growth factors and oxidation of C106, DJ-1 translocates to the nucleus playing a role in 
antioxidant gene regulation [109]. In cells undergoing oxidative stress DJ-1 is localised 
to the outer mitochondrial membrane (OMM), to maintain a healthy mitochondrial 
environment [110]. With its role in mitochondrial homeostasis and early onset of PD, the 
potential relationship between α-synuclein and DJ-1 is of interest. Jin et al. (2007) 
analysed proteins associated with α-synuclein and/or DJ-1 using stable isotope labelling 
by amino acids in cell culture (SILAC). This was conducted in dopaminergic mouse 
embryonic stem cells (ESCs) exposed to rotenone. Rotenone is an inhibitor of the 
electron transport chain used in cellular models of PD [111]. Although Jin et al. (2007) 
did not observe a direct interaction between α-synuclein and DJ-1, they shared 114 
protein interaction partners with the relative abundance of those proteins altered 
significantly after rotenone treatment [111]. This work reported five novel proteins that 
associate with both α-synuclein and DJ-1 including mortalin.  
Mortalin is a mitochondrial stress protein which is a part of the mitochondrial import 
complex. As part of this complex, mortalin acts as a molecular chaperone for the import 
of nuclear-encoded protein into the mitochondria via the inner mitochondrial membrane 
(IMM) translocases [112]. Mortalin has a functional role in mitochondrial homeostasis 
and as such there is interest in its potential involvement in PD development via pathways 
involving mitochondria, the proteasome and oxidative stress [113].  
Overexpression of α-synuclein has been found to fragment mitochondria in neurons 
preceding deterioration of mitochondrial function [114]. This process occurred through 
promotion of fission requiring a direct interaction of α-synuclein with mitochondrial 
membranes, allowing it to remodel them [26]. 
α-synuclein was also shown to dysregulate mitophagy. In cortical neurons transfected 
with mutant A53T α-synuclein, the level of healthy mitochondria colocalising with 
autophagosomes was increased. This was associated with decreased ATP levels 
resulting in bioenergetic deficits in the neurons. In this context, the role of Parkin, which 





4.6.4. Endoplasmic reticulum 
The Endoplasmic reticulum (ER) is involved in a variety of functions including lipid 
biosynthesis, protein folding and sorting, and calcium storage. The unfolded protein 
response (UPR) is a stress response that originates from the ER when there is an 
increase of unfolded protein in its lumen. The chaperone glucose regulated protein 78 
(GRP78/BIP) binds to the luminal domain of stress sensors in the ER and dissociates 
upon binding to unfolded proteins which results in the initiation of stress signals [46]. α-
synuclein has been shown to directly interact with GRP78/BIP [106] and the stress 
sensors [116]. The expression of GRP78/BIP decreases with age, however, in PD 
patients an increase occurs in brain tissue affected by α-synuclein pathology [117]. This 
suggests that accumulation of misfolded α-synuclein in the ER can act as a trigger of the 
UPR in synucleinopathies. 
 
4.6.5. Microtubules 
MAPT, which encodes the microtubule associated protein tau, has been investigated as 
a candidate gene in PD due to the shared neuropathological characteristics between a 
number of neurodegenerative diseases. Brain tissue from AD, tauopathies and PD all 
show aggregation of intraneuronal hyperphosphorylated Tau [118]. MAPT is located on 
chromosome 17 in an interval that is characterised by a large inversion with two 
haplotypes, H1 and H2. In Caucasian populations H1 has been identified as a genetic 
risk factor for PD [119]. 
Tau pathology in PD is often accompanied with α-synuclein pathology [120]. α-synuclein 
fibrils bind to tau through an ionic interaction and inhibit tau from aiding microtubule 
assembly. Although this interaction may not be crucial for the formation of LBs or PD 
pathogenesis, it has been shown that when incubated together they synergistically 
promote fibrilization [121]. α-synuclein fibrils may interact with other microtubule 
associated proteins (MAPs) as they have similar microtubule binding domains to tau. 
Levels of MAPs may be reduced in neurons resulting in disruption of the microtubule 
network and subsequent neuronal death. Microtubules play a major role in transport of 
mitochondria, vesicles and organelles. Therefore, disruption of their functions in axons 








4.7. Proteomics and the study of disease mechanisms in PD 
4.7.1. Principles of proteomics 
With increasing knowledge of the genetics of PD, the mechanisms of disease pathology 
and progression can be determined, one way this can be achieved is with proteomics. 
While the genome is more or less constant, the proteome of an organism differs between 
cell types as well as with time. Proteomics is a powerful approach to confirm the presence 
and quantity of proteins. Commonly, proteins may be detected using immunoassays or 
mass spectrometry (MS), however approaches have evolved over the past two decades, 
with the number of proteins that can be analysed in a single sample increasing from 
hundreds two decades ago to thousands today [123]. 
Before MS analysis, proteins are subjected to tryptic digestion, producing peptides. The 
peptides are then ionized, the most common method used is electrospray ionisation 
(ESI). The ESI process involves transferring ions from solutions to gaseous phase. 
Under high voltage, the sample solution, containing sample peptides and solvent 
typically in water, is released from a capillary needle in the form of liquid droplets [124]. 
The charged droplets are accelerated towards a counter charge electrode, passing 
through heated gas [125]. The solvent in the droplets progressively evaporates further 
concentrating the charge [126]. The resulting ions are separated according to their mass-
to-charge ratio (m/z). This is typically done by subjecting them to a magnetic field, ions 
with different mass-to-charge ratios are deflected to a different degree. The ions are 
detected and the results are displayed as a spectra of signal intensity of detected ions. 
Proteins in the sample are then identified by comparison of known masses or 
characteristic fragmentation patterns with the identified masses [127].  
Tandem mass spectrometry (MS/MS) analyses samples using two or more mass 
analysers coupled together. After the sample has been ionised, the first spectrometer 
separates the ions by their m/z. Ions with particular m/z ratios are then split into smaller 
fragment ions. Collision induced dissociation (CID) is the most common method of 
fragmentation. In the presence of inert gases, ions collide with each other causing them 
to form smaller defined masses based on their amino acid sequence [126]. Fragmented 
ions are separated further by a second spectrometer, their spectra are then used to 







Database matching of MS/MS data is possible because the peptide ions fragment 
preferentially at certain points along the backbone [129]. However, fragmentation is not 
a clean process and the spectrum will often show peaks from side chains and internal 
fragments, which is why database searches comparing peptides to candidate peptide 
sequences is essential. When comparing the MS/MS to the candidate sequences, the 
pool may be limited meaning that the best match is accepted as the correct sequence. 
For example, if there is no sequence from one half of a peptide in the database but the 
other half is present and the molecular mass matches, this is accepted as the correct 
sequence [129]. 
Initial approaches for database searches of MS/MS data involved selection of sequence 
tags. These consisted of choosing a short sequence of residues that when combined 
with the fragment ion mass values that enclose the sequence, peptide mass and the 
specificity of the enzyme used to produce the initial peptides, inferred the peptide’s 
protein of origin [130]. Due to the expertise required for the selection of appropriate tags, 
this technique has been superseded by direct searches of the MS/MS peak list [129]. 
The method of comparing experimental MS/MS spectra against that predicted from 
candidate peptide sequences had led to the creation of a variety of programs both local 
and online for performing searches of uninterpreted MS/MS data. All search engines 
support searching of protein databases with some supporting the search of DNA 
sequences [129]. 
While proteomic analysis can be used to qualitatively identify thousands of proteins in 
biological samples, there is also a need to quantitate them. Global protein dynamics can 
be studied on a cellular and tissue level using quantitative proteomics which is critical for 
understanding protein kinetics and the mechanisms of biological processes.  
MS/MS is the basis of several quantitative proteomic methods such as tandem mass 
tagging (TMT). TMT is a quantitative proteomic approach which allows several samples 
to be analysed at once. Peptides are labelled with isobaric tags that consist of a mass 
reporter, a mass normalizer and an amine reactive group (Fig. 11A). Each tag has the 
same overall structure and mass but vary in the distribution of heavy isotopes within the 
FIGURE 10. Schematic showing the stages of tandem mass spectrometry. The sample is ionized, 
most commonly through by electrospray ionisation (ESI), this produces a mixture of ions. Ions of a specific 
mass to charge ratio (m/z) are selected (MS1). Selected ions are fragmented usually through collision 
induced dissociation (CID). The resulting fragment ions are separated again (MS2). The spectrum of the 




mass reporter region which is identified during the second round of MS [131], (Fig. 11B). 
These differences mean that when the mass reporter is cleaved during the second round 
of MS they can be identified in order of mass [132]. 
TMT allows digested peptides from multiple samples to be labelled with as many as ten 
tag variants [131]. After proteins have been denatured and digested, they are labelled 
with TMT. The differentially labelled samples are then combined and subjected to MS/MS 
as outlined above in Figure 10. TMT not only allows for identification of the peptides 
present in the samples but also their relative abundance through comparison of the 






















Another quantitative method is stable isotope labelling by amino acids in cell culture 
(SILAC). SILAC involves labelling protein samples by growing cells in media containing 
FIGURE 11. Structure of TMT reagents. A) TMT reagent consisting of a mass reporter, mass normalizer 
and amine reactive group. B) 10plex TMT. Heavy labelled C12 and N13 are indicated by asterisks (Figure 




heavy and light forms of an amino acid. Cell lysates are mixed, from which the proteins 
are extracted and digested. The samples are then analysed by MS [123, 133], (Fig. 12). 
The difference in isotope mass allows for the signals of each cell type to be identified 
and compared. This method is useful for detecting relatively small changes in protein 
levels or post-translational modifications as the labelling is introduced early in the 
workflow and is therefore retained throughout the processing steps [126]. 
 
 
4.7.2. Proteomic analysis of Interactions with α-synuclein 
Proteomics is useful for elucidating the role of α-synuclein in PD and other 
synucleinopathies. This is largely due to the ability to map thousands of interactions or 
changes in protein levels within a single sample. As more information is gathered, it will 
become clearer as to how the role of α-synuclein changes under pathogenic conditions 
and the implications it has on the progression of PD and other synucleinopathies. 
α-synuclein has been suggested to play a role in synaptic homeostasis. Identifying its 
interaction partners will provide insight into its function under physiological and 
pathological conditions. Under pathological conditions where α-synuclein is present in 
LBs, it is mostly phosphorylated at Ser-129, occurring in both familial and sporadic Lewy 
body diseases, such as PD [134]. The extent of α-synuclein phosphorylation and its 
aggregation in LBs as steps in disease pathogenesis is still controversial. Pulldown 
assays were utilised to analyse the protein-protein interactions of phosphorylated and 
non-phosphorylated α-synuclein. The use of targeted functional proteomics such as 
pulldown assays provides a broad and unbiased look at protein networks and how they 
FIGURE 12. The principle of SILAC. During the adaptation phase, cells are grown in light and heavy 
SILAC medium until heavy amino acids are fully incorporated into the growing cells. During the 
experimental phase, the two cell populations are subjected to different treatments according to the 
research aim. The cell populations are mixed and the proteins are digested into peptides. Samples are 






may change as the result of post-translational modifications. This simple approach 
allowed for observation of globular cell interactions of α-synuclein [134].  Protein 
pulldown assays showed that non-phosphorylated α-synuclein protein complexes were 
enriched for mitochondrial proteins whereas, the proteins pulled down by phosphorylated 
α-synuclein were of cytoskeletal and vesicular trafficking origin [134]. Alongside α-
synuclein, LBs have been shown to contain a variety of proteins including cytoskeletal 
proteins, MAP1B and tau [111].  As phosphorylated α-synuclein was shown to interact 
with cytoskeletal elements, their presence in LBs suggests that the production of LBs 
likely results in-part from these interactions [134]. 
Mitochondria are the most studied organelle for understanding the pathology of PD due 
to the autosomal recessive mutations observed in the genes encoding the proteins 
PINK1, DJ-1 and Parkin which are involved in mitochondrial quality control [135]. Death 
of dopaminergic neurons resulting from induction of oxidative stress and apoptotic 
pathways involving mitochondria provides evidence of their contribution to the pathology 
of PD, the extent of which needs to be determined [136]. MS/MS was used to quantitate 
any changes in protein expression upon overexpression of α-synuclein in transgenic 
mice. Overexpression of α-synuclein led to the downregulation of mitochondrial complex 
I and IV but upregulation of complex III of the electron transport chain. With α-synuclein 
overexpression causing mitochondrial dysfunction it was suggested that α-synuclein 
could down regulate complex I and IV and that the upregulation of complex III was a 
compensatory measure by the cell [137]. Further work will need to determine whether 
this effect is also observed in human PD pathology, if so, it could provide a greater 
understanding of the role α-synuclein plays in mitochondrial dysfunction.  
Despite clinical benefits of supplementing dopamine levels in PD patients, it has been 
suspected that dopamine may contribute to PD pathogenesis [138]. Proteomics was 
used to investigate the interplay between α-synuclein and dopamine in the SH-SY5Y 
human neuroblastoma cell line [139]. Proteins involved in protein synthesis were less 
abundant after dopamine treatment suggesting reduced expression under cellular stress 
conditions [139]. Changes in mitochondrial protein expression were also observed, 
including the disappearance of VDAC2 upon treatment with dopamine. VDAC2 is a porin 
of the outer-mitochondrial membrane which regulates mitochondrial calcium 
homeostasis and mitochondrial-dependent cell death, two major factors in PD [140]. An 
enriched network model was produced to deduce whether proteins differentially 
expressed were involved in the same network. This procedure suggested potential 
involvement of the NF-κB pathway and apoptosis regulation, later shown experimentally 




When dopamine is not degraded or packaged into synaptic vesicles it becomes oxidised, 
generating quinones and reactive oxygen species. Extensive evidence has indicated that 
oxidised dopamine inhibits the aggregation of α-synuclein [141]. Consistent with this, 
elevation of dopamine levels in SH-SY5Y cells expressing A53T α-synuclein resulted in 
a reduction of aggregates and an increase in soluble oligomers [141]. Mor et al. (2017) 
tested the effects in vivo, examining α-synuclein in the SN of A53T mice. In the A53T 
control mice which had been injected with an empty vector, inclusion pathology was 
absent in the SN, there was no alteration in the levels of insoluble α-synuclein rather they 
presented a reduction in α-synuclein monomers and an increase in oligomers of different 
conformations. These findings suggested that the toxicity of dopamine-induced 
oligomers is not dependent on seeding [142]. Concurrent with this, expression of WT 
and A53T α-synuclein in dopaminergic neurons in C. elegans has been shown to cause 
neuronal dysfunction and death with increased cytosolic dopamine accumulation [143]. 
These studies indicate a relationship between dopamine and α-synuclein in the induction 
of neuronal cell death. 
As shown by the presence of GCIs in MSA, aggregated α-synuclein does not just affect 
neurons in synucleinopathies. In fact, aggregated α-synuclein has been shown to 
activate microglia which play a major role in neuroinflammation [144]. Liu et al. (2007) 
aimed to elucidate the mechanism by which aggregated α-synuclein enters microglia 
using SILAC on primary cultured microglia. They identified 46 microglial membrane 
proteins whose relative abundance was altered after α-synuclein treatment. Of these 
proteins, clathrin and calnexin were further evaluated. For the first time they were able 
to show that microglial endocytosis of aggregated α-synuclein may involve the classic 
clathrin-mediated endocytic pathway due to the co-localisation of clathrin and 
aggregated α-synuclein within the microglia [144]. 
 
4.7.3. LBs  
LBs themselves are valuable samples for proteomic investigations, with these inclusions 
being a histopathological hallmark of PD and other synucleinopathies. As mentioned 
previously, there are several proteins present in LBs aside from α-synuclein, which may 
or may not be relevant to PD progression. Henderson and colleagues performed 
proteomic analysis on insoluble proteins in a primary neuron model of α-synuclein 
pathology to identify proteins involved in early LB formation [145]. This approach involved 
the use of liquid chromatography-MS/MS. As this study aimed to identify a number of 
proteins, MS/MS was essential for their identification [145]. Several novel proteins were 
identified in LBs including the microtubule affinity-regulating kinase 1 (MARK1), [145]. 




decrease of tau binding to microtubules and their subsequent destabilisation or alteration 
of microtubule-dependent transport [146]. Moreover, MARKs have been implicated in PD 
pathways. MARK2 was shown to activate a cleaved form of PINK1, while MARK1 has 
been identified as a direct substrate of LRRK2, mutations of which are implicated in PD. 
These findings suggest that MARKs may play a role in the pathogenesis of PD, the extent 
of which will be determined in future studies [145]. 
Although the presence of LBs is the pathological hallmark of PD, models commonly used 
to study the disease have not exhibited the biochemical complexity of LBs in post-
mortem brains of PD patients, instead, reproducing specific aspects or stages of LB 
pathology formation [147]. As these models have not shown the transition from α-
synuclein fibrils to LB inclusions, the different stages of LB pathology formation remain 
to be elucidated. Recent work by Mahul-Mellier et al. (2020) aimed to address this using 
a cellular seeding-based mouse model. When culturing neurons for proteomic analysis, 
they extended the seeding process of α-synuclein preformed fibrils from 14 to 21 days, 
allowing for the formation of LB-like inclusions [147].  
Using probes that target different types of lipids they were able to detect several classes 
of lipids present in their seeding model which are bona fide components of LB inclusions 
derived from post-mortem PD brains, demonstrating that their model recapitulates 
processes in LB formation. Mahul-Mellier et al. (2020) used proteomics to compare their 
model to LBs from human brain tissue, with a quarter of the proteins identified in their 
inclusion data at day 14 and 21 being described previously as components of LBs [148]. 
In their model, the formation of α-synuclein fibrils occurred as early as days 4-7 with no 
effect on neuronal viability up to day 14, suggesting that α-synuclein fibrillization is not 
sufficient to trigger neuron death. As LBs began to form between days 14 and 21, cell 
function became impaired leading to the conclusion that it is the formation of LBs rather 
than α-synuclein fibril formation that is the major factor in α-synuclein toxicity [147]. 
Proteomics was crucial in this study as it allowed for observation of changes in the global 
cell proteome both in cellular models and patient samples. 
 
4.8. Project Aim 
4.8.1. Aim 
Although it is known that exogenous α-synuclein fibrils can be taken up by cells and 
induce aggregation of endogenous α-synuclein intro intracellular inclusions, there is little 
known about the initial cellular response to uptake. It is also unclear at present as to the 
events between uptake and initial inclusion formation. Proteomics has provided novel 




approach for observing changes in protein levels in a cell in response to external factors. 
Proteomics is therefore a useful method for understanding cellular response upon 
exposure to α-synuclein fibrils. It can be utilised to detect the presence of α-synuclein in 
samples such as whole cell lysates, as well as identification of α-synuclein interaction 
partners. This kind of data is crucial for understanding the effects of α-synuclein 
aggregation. With the transmission of α-synuclein aggregates known to occur in several 
ways, identification of pathways associated with α-synuclein can elucidate how such 
aggregates are implicated in cellular dysfunction and ultimately neuronal death.   
This project aims to examine the response of cells upon initial exposure to extracellular 
α-synuclein fibrils and after the fibrils have seeded endogenous inclusions. Proteomics 




1. Establish and characterise a cellular model to study the effect of exogenous α-
synuclein fibrils on cells. 
2. Analyse the effect that exposure to exogenous α-synuclein has on the cellular 
proteome. 
3. Use bioinformatics tools to analyse the changes in the cellular proteome and 
determine the functional consequences for the cells. 
 
5. Results 
5.1. Characterisation of an experimental model for the study of the effects of exogenous 
α-synuclein fibrils on cells 
In this project the effect of α-synuclein fibrils on the proteome of the neuroblastoma cell 
line SH-SY5Y GFP-α-synuclein was observed. This cell line was chosen as it 
overexpresses α-synuclein and it can act as a model for LB formation, with exogenous 
fibrils promoting α-synuclein aggregation into intracellular inclusions [149]. However, it 
was necessary that the cellular model was characterized prior to proteomic analysis to 
observe the effects that α-synuclein fibrils had on GFP-α-synuclein cells. This involved 
determining the toxicity of α-synuclein fibrils on the cells, observing the internalisation of 





5.1.1. Characterisation of the effect of α-synuclein fibrils on SH-SY5Y GFP-α-synuclein 
cell viability 
The SH-SY5Y GFP-α-synuclein cell line used for this project was derived from the 
neuroblastoma SH-SY5Y cell line which had been stably transfected with GFP-α-
synuclein [150, 151]. The GFP-α-synuclein fusion is 49 kDa in size, it has GFP at the N-
terminus, a short linker region followed by the full-length wild type α-synuclein sequence 
at the C-terminus (Fig. 13). The GFP-α-synuclein can be visualised by confocal 
microscopy, appearing green when imaged. As the fusion protein was overexpressed in 
the SH-SY5Y GFP-α-synuclein cell line, it was easy to visualise during microscopy. 
Furthermore, with the ability of SH-SY5Y GFP-α-synuclein cells to be seeded, forming 
cytoplasmic inclusions upon incubation with α-synuclein fibrils, this cell line can serve as 
a model of LB formation.  
 
 
5.1.2. Production of Alexa Fluor 594-labelled α-synuclein fibrils 
α-synuclein fibrils used in this project were labelled with a fluorescent dye to enable 
them to be visualised using fluorescence microscopy. Labelled fibrils for use in this 
project were produced and provided by Michael Davies of the Hewitt research group.  
Briefly, monomeric α-synuclein was labelled with Alexa Fluor 594 on lysine residues by 
N-Hydroxysuccinimide (NHS) chemistry, and unreacted label removed by size 
exclusion chromatography. Labelled and unlabelled monomeric α-synuclein were 
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FIGURE 13. Schematic of the GFP-α-synuclein protein. The fusion protein is 49 kDa in size. The GFP 
region (green) is connected to the α-synuclein region (pink) via a short linker region (black). The predicted 

















5.1.3. Analysis of the impact of α-synuclein fibrils on cell viability 
In initial experiments the response of the SH-SY5Y GFP-α-synuclein cells to incubation 
with α-synuclein fibrils, was characterised by determining if the fibrils were toxic to these 
cells. Three different assays were used, each measuring an aspect of cellular function 
and in combination they could infer whether the addition of fibrils affected cell viability. 
 
5.1.3.1. Analysis of the effect of α-synuclein fibrils on cellular Adenosine Triphosphate 
(ATP) levels 
ATP is present in metabolically active cells and is therefore a marker for cell viability. The 
ATPlite assay system is based on the production of light caused by the reaction of ATP 
with added luciferase and D-luciferin [152], (Fig. 15). The light that is emitted is directly 
proportional to the ATP concentration of the cells within samples; reduced levels of ATP 






FIGURE 14. EM image of sonicated Alexa Fluor 594-labelled α-synuclein fibrils. Fibrils were 
produced by incubation of 500 µM monomeric α-synuclein with 5% Alexa Fluor 594-labelled monomer for 
3 days at 42°C and constantly agitated at 1500 rpm. Image produced by Michael Davies of the Hewitt 
research group. Scale bar = 100 nm. 
ATP + D-Luciferin + O2                           Oxyluciferin + AMP + PPi + CO2 + Light 
Luciferase 
Mg2
FIGURE 15. Schematic of the reaction during the ATP assay. This assay uses firefly luciferase to 
convert ATP and luciferin to oxyluciferin and light. The amount of light emitted in this reaction is directly 




SH-SY5Y GFP-α-synuclein cells were incubated for 24 hr in the presence or absence of 
Alexa Fluor 594-labelled α-synuclein fibrils or PBS buffer prior to the ATP assay. 
Immediately before the assay, control cells were lysed with detergent containing buffer, 
causing cell death and subsequent reduction in the level of ATP. These cells served as 
a background reading against which the sample cells were compared. Once the assay 
was complete the luminescence of each sample was measured. 
There was no luminescence observed in the lysis control cells, however, upon 
comparison there was luminescence which did not differ significantly between cells 
incubated with fibrils and cells incubated with the PBS buffer control. This demonstrated 




















































A B  
FIGURE 16. ATP assay conducted on SH-SY5Y GFP-α-synuclein cells after 24 hr incubation with 
Alexa Fluor 594-labelled α-synuclein fibrils. Cells were incubated with 1 µM Alexa Fluor 594-labelled α-
synuclein fibrils (final concentration monomer equivalent) in PBS, equivalent volume of PBS or untreated 
for 24 hr. Lysis control samples were treated with 20 µL lysis buffer prior to assays. A: Luminescence 
measured after ATP assay. AU, arbitrary units. B: ATP assay normalised to cells incubated with PBS. 
Results are expressed as mean ± 1 S.E.M, n=3. Welch’s ANOVA and Dunnett’s T3 multiple comparison 
tests were used for analysis of the data set (ns, not significant). The assay was conducted in triplicate 
each with nine replicates. 
 Mean Difference Adjusted p-value 
Untreated vs PBS 11.73 0.1661 
Untreated vs Fibrils 7.848 0.8374 
Untreated vs Lysis control 111.7 <0.0001 
PBS vs Fibrils -3.883 0.9940 
PBS vs Lysis control 99.94 <0.0001 
Fibrils vs Lysis control 103.8 <0.0001 
 
TABLE 1. Dunnett’s T3 multiple comparisons test of ATP assay on SH-SY5Y GFP-α-synuclein cells 





5.1.3.2. Analysis of the effect α-synuclein fibrils has on the cellular release of Lactate 
Dehydrogenase (LDH)  
LDH is a soluble cytosolic enzyme and damage to the plasma membrane results in the 
release of LDH into the cell media. For example, during the initial stages of apoptosis, 
the cytoskeleton breaks up resulting in membrane blebbing, this leads to damage of the 
plasma membrane through which cytosolic contents are released [153]. The release of 
LDH can be used to determine the level of membrane damage in cells and thus infer 
whether there is any reduction in cell viability. The amount of LDH released into the 
media can be quantified by the following reaction. LDH catalyses the conversion of 
lactate to pyruvate via NAD+ reduction to NADH. In the assay, diaphorase then uses 
NADH to reduce INT to a red formazan product that can be measured at 490nm [154], 
(Fig. 17). The level of formazan produced is directly proportional to the amount of LDH 
released into the medium. 
 
 
SH-SY5Y GFP-α-synuclein cells were incubated for 24 hr in the presence or absence of 
Alexa Fluor 594-labelled α-synuclein fibrils or PBS buffer prior to the LDH assay. 
Immediately before the assay, positive control cells were lysed with detergent containing 
buffer. This permeabilised the plasma membrane allowing these cells to serve as a 
background reading for LDH release into the medium.  
The level of LDH released into the medium did not differ significantly between cells 
treated with PBS or fibrils. This demonstrated that the fibrils did not cause any significant 
damage to the plasma membrane (Fig. 18), (Table 2).  
FIGURE 17. Schematic of the enzymatic reaction during the LDH assay. LDH catalyses the 
conversion of lactate to pyruvate which is concomitant with the reduction of NAD+ to NADH. Diaphorase 
utilises NADH to reduce INT to a red formazan product allowing for colorimetric quantification (Figure 





5.1.3.3. Analysis of the effect α-synuclein fibrils has on the cellular reduction of 3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) 
The MTT assay is a colorimetric assay for assessing cell metabolic activity. MTT is 
reduced to insoluble purple formazan via NADPH dependent oxidoreductase enzymes. 
The level of formazan produced is directly proportional to the amount of MTT reduced 



















































FIGURE 18. LDH assay conducted on SH-SY5Y GFP-α-synuclein cells after 24 hr incubation with 
Alexa Fluor 594 labelled α-synuclein fibrils. Cells were incubated with 1 µM Alexa Fluor 594 labelled α-
synuclein fibrils (final concentration monomer equivalent) in PBS, equivalent volume of PBS or untreated 
for 24 hr. LDH positive control samples were treated with 20 µL LDH lysis buffer prior to assays. A: 
Absorbance measured at 485/620 nm after LDH assay. B: LDH assay normalised to PBS. Results are 
expressed as mean ± 1 S.E.M, n=3. Kruskal-Wallis and Dunn’s multiple comparisons tests were used for 
analysis of the data set (ns, not significant). The assay was conducted in triplicate each with nine 
replicates. 
 Mean Rank Difference Adjusted p-value 
Untreated vs PBS 6.944 >0.9999 
Untreated vs Fibrils 0.500 >0.9999 
Untreated vs Lysis control -42.52 0.0001 
PBS vs Fibrils -6.444 >0.9999 
PBS vs Lysis control -49.46 <0.0001 
Fibrils vs Lysis control -43.02 0.0001 
 
TABLE 2. Dunn’s multiple comparisons test of LDH assay on SH-SY5Y GFP-α-synuclein cells 
incubated with α-synuclein fibrils for 24 hr. 
FIGURE 19. Schematic of the reaction during the MTT assay. MTT is reduced to insoluble purple 





SH-SY5Y GFP-α-synuclein cells were incubated for 24 hr in the presence or absence of 
Alexa Fluor 594-labelled α-synuclein fibrils or PBS buffer prior to the MTT assay. 
Immediately before the assay, control cells were lysed. This caused cell death, providing 
a background level of MTT reduction against which the cells incubated with PBS and 
fibrils could be compared.  
There was a small, but not statistically significant, decrease in the reduction of MTT for 
cells incubated with fibrils when compared to cells incubated with PBS samples. These 
data support the outcome of the other assays, whereby addition of fibrils is not cytotoxic 
to SH-SY5Y GFP-α-synuclein cells (Fig. 20), (Table 3). 
 
 
5.1.4. Analysis of fibril uptake and localisation in SH-SY5Y GFP-α-synuclein cells 
As the incubation of SH-SY5Y GFP-α-synuclein cells with fibrils did not result in cell 
death, the interaction of fibrils with the cells was investigated next.  
A B  
FIGURE 20. MTT assay conducted on SH-SY5Y GFP-α-synuclein cells after 24 hr incubation with 
Alexa Fluor 594 labelled α-synuclein fibrils. Cells were incubated with 1 µM Alexa Fluor 594 labelled α-
synuclein fibrils (final concentration monomer equivalent) in PBS, equivalent volume of PBS or untreated 
for 24 hr. Lysis control samples were treated with 20 µL lysis buffer prior to assays. A: Absorbance 
measured at 570 nm after MTT assay. B: MTT assay normalised to PBS. Results are expressed as mean 
± 1 S.E.M, n=3. Kruskal-Wallis and Dunn’s multiple comparisons tests were used for analysis of the data 
set (ns, not significant). The assay was conducted in triplicate each with nine replicates. 
 Mean Rank Difference Adjusted p-value 
Untreated vs PBS -10.04 >0.9999 
Untreated vs Fibrils 3.271 >0.9999 
Untreated vs Lysis control 58.74 <0.0001 
PBS vs Fibrils 13.31 0.6913 
PBS vs Lysis control 68.79 <0.0001 
Fibrils vs Lysis control 55.47 <0.0001 
 
TABLE 3. Dunn’s multiple comparisons test of MTT assay on SH-SY5Y GFP-α-synuclein cells 





To analyse the interaction of α-synuclein fibrils with the SH-SY5Y GFP-α-synuclein cell 
line confocal microscopy was used, in order to observe the uptake and subsequent 
localisation of the fibrils. Upon endocytosis, fibrils are trafficked to the lysosomes. This 
has been shown previously in the SH-SY5Y cell line whereby after 24 hr exposure to 
Alexa Fluor 647-labelled α-synuclein fibrils, co-localisation of the fibrils with the 
lysosomal marker LAMP-1 was observed [156].  
SH-SY5Y GFP-α-synuclein cells were incubated for 24 hr in the presence or absence of 
Alexa Fluor 594-labelled α-synuclein fibrils. After the incubation, LysoTracker Deep Red 
was used to identify lysosomes. Lysotracker probes are freely permeant to the cell 
membrane with a high selectivity for acidic organelles such as the lysosomes [157]. 
LysoTracker Deep Red was used during imaging as it allowed for multiplex imaging with 
GFP and Alexa Fluor 594 [157]. 
Live cell confocal microscopy demonstrated that Alexa Fluor 594-labelled α-synuclein 
fibrils exhibited a punctate distribution with a degree of co-localisation with the 
LysoTracker after 24 hr incubation. It can therefore be inferred that a proportion of the 
fibrils were internalised and sorted to lysosomes (Fig. 21). The same confocal imaging 
analysis was then applied to a 5-day incubation, after which co-localisation of Alexa Fluor 
594-labelled α-synuclein fibrils with lysosomes was still present (Fig. 22). These results 
are consistent with other studies in which fibrils were shown to be internalised and 













C Lysotracker Fibrils Merge Merge 
D Lysotracker Fibrils Merge Merge 
E Lysotracker Fibrils Merge Merge 
FIGURE 21. Live cell confocal microscopy of α-synuclein fibrils incubated with SH-SY5Y GFP-α-
synuclein cells for 24 hr. GFP-α-synuclein SH-SY5Y cells were incubated for 24 hr in the presence or 
absence of 1 µM Alexa Fluor 594-labelled α-synuclein fibrils (monomer equivalent concentration), or 10 µL 
PBS buffer. A: PBS buffer. B-E: Alexa Fluor 594-labelled α-synuclein fibrils, Cells were imaged in media 
containing Hoechst and deep red Lysotracker. Lysotracker is presented in green and fibrils are presented in 
magenta. In the merged images, white arrows indicate co-localisation of fibrils with Lysotracker, yellow 
boxes highlight the origin of the zoomed in merge images. Images are presented with false colouring. 






FIGURE 22. Live cell confocal microscopy of α-synuclein fibrils incubated with SH-SY5Y GFP-α-
synuclein cells for 5 days. GFP-α-synuclein SH-SY5Y cells were incubated for 5 days in the presence or 
absence of 1 µM Alexa Fluor 594-labelled α-synuclein fibrils (monomer equivalent concentration), or 10 µL 
PBS buffer. A: PBS buffer. B-E: Alexa Fluor 594-labelled α-synuclein fibrils, Cells were imaged in media 
containing Hoechst and deep red Lysotracker. Lysotracker is presented in green and fibrils are presented 
in magenta. In the merged images, white arrows indicate co-localisation of fibrils with Lysotracker, yellow 
boxes highlight the origin of the zoomed in merge images. Images are presented with false colouring. 




5.1.5. Analysis of the seeding of intracellular GFP-α-synuclein by exogenous fibrils in 
SH-SY5Y GFP-α-synuclein cells 
With the presence of α-synuclein fibrils in LBs, there has been much research on 
elucidating the mechanism for the formation of inclusions. α-synuclein fibrils have been 
suggested to have prion-like properties, whereby α-synuclein aggregates generated in 
one cell are transferred to neighbouring neurons via the synapse, acting as a template 
for misfolding of α-synuclein in the recipient neurons [53, 54, 56]. As shown herein, after 
internalisation, α-synuclein is trafficked to the lysosomes via the endocytic pathway.  
However, the prevailing hypothesis for fibril formation suggests that some α-synuclein 
escapes the endocytic pathway into the cytosol, where it can interact with intracellular 
monomeric α-synuclein [47]. Through this interaction it is believed that pathogenic α-
synuclein can cause intracellular α-synuclein monomers to form insoluble fibrils [48].  
It has previously been shown that seeding of α-synuclein can occur as early as 5-days 
in vitro through incubation of cells with α-synuclein fibrils. Preformed fibrils were shown 
to be endocytosed by primary neurons and induced recruitment of endogenously 
expressed α-synuclein into insoluble aggregates after 5-days incubation [147].    
The final stage of characterising the cellular model involved demonstrating that exposure 
of SH-SY5Y GFP-α-synuclein cells for 5 days to exogenous fibrils can seed the 
aggregation of cytosolic α-synuclein, thus recapitulating previous observations in mouse 
primary neuronal cultures [147, 149]. The goal was to demonstrate the formation of 
insoluble GFP-α-synuclein inclusions within the cells as shown previously [147, 149]. In 
this seeding assay only a small percentage of GFP-α-synuclein formed insoluble 
inclusions. To visualise these inclusions, soluble GFP-α-synuclein was removed by 
permeabilising the cells with saponin detergent before fixation. After 5-days incubation 
in the absence of fibrils, no inclusions were observed.  However, upon exposure to α-
synuclein fibrils, detergent insoluble GFP-α-synuclein puncta were observed, consistent 
with the formation of intracellular inclusions (Fig. 23). This demonstrates that the cell 
model can recapitulate seeding of α-synuclein aggregation by exogenous fibrils and as 
such, it can be used as a model system for the cellular effects of α-synuclein fibrils on 











Having demonstrated experimentally that α-synuclein inclusions can form in the SH-
SY5Y GFP-α-synuclein cells, combined with the cell line’s overexpression of GFP-α-
synuclein, they are ideal for use in proteomic analysis of protein changes resulting from 
the formation of α-synuclein inclusions. 
FIGURE 23. Insoluble inclusions of α-synuclein are present after a 5-day seeding assay with α-
synuclein fibrils.  SH-SY5Y GFP-α-synuclein cells were incubated for 5 days in the presence of 1 µM 
Alexa Fluor 594-labelled α-synuclein fibrils (monomer equivalent concentration), or 10 µL PBS buffer. A: 
PBS buffer. B-E: Alexa Fluor 594-labelled α-synuclein fibrils. Cells were permeabilised with saponin to 
remove soluble GFP-α-synuclein prior to fixation followed by staining with Hoechst in PBS buffer. GFP-α-
synuclein inclusions (green), nuclei (blue), yellow boxes highlight the origin of the zoomed in merge 






5.2. Sample preparation for proteomic analysis 
Having demonstrated that the experimental model, SH-SY5Y GFP-α-synuclein cells, can 
take up exogenous α-synuclein fibrils and that these can then seed α-synuclein 
aggregation, it can therefore be used as a model to study cellular effects of α-synuclein 
fibril uptake and the cellular effects of α-synuclein aggregation in the cytosol. To study 
this, proteomic analysis of the SH-SY5Y GFP-α-synuclein cells was conducted to 
observe whether the expression of proteins was altered in response to these events. 
Having established the lack of toxicity α-synuclein fibrils have on the cell-system, whole 
cell lysate samples were prepared for proteomic analysis. SH-SY5Y GFP-α-synuclein 
cells were plated in triplicate with three independent experimental repeats for each 
timepoint: 0, 1 and 5-days incubation with Alexa Fluor 594-labelled α-synuclein fibrils. 
Cells were cultured for a total of 6 days. After 24 hrs, fibrils were added to the 5-day 
dishes, then to the 1-day dishes after another 4 days. This allowed for collection on the 
same day and comparison of cells at the same stage of growth, subjected to different 
lengths of fibril incubation. Cell lysates were produced from the SH-SY5Y GFP-α-
synuclein cells and a bicinchoninic acid (BCA) assay was used to determine the protein 
concentration of each sample, this ensured equal amounts of protein in each sample 
sent for proteomic analysis.  
Samples of cell lysates containing at least 2 mg/mL of protein were selected for further 
analysis as they contained sufficient protein for TMT-MS analysis. The presence of 
protein within each sample was confirmed by separating samples on an acrylamide gel 
(Fig. 24). With protein presence confirmed, 50 µg of each sample was sent to the 




























5.3. Proteomics reveals quantitative changes in proteins from whole cell lysates 
incubated with α-synuclein fibrils 
TMT-MS identified a total of 7263 proteins present in the whole cell lysate samples. After 
excluding contaminants and proteins presenting less than two unique peptides, this was 
reduced to 5802 proteins. Comparison of these proteins to a previously published 
proteome of the SH-SY5Y cell line revealed a coverage of 50.03% with the whole cell 
lysate proteins matching 2619 of the 5235 proteins of the SH-SY5Y cell line [158]. 3183 
proteins from the whole cell lysates were absent in the previously published proteome. 
Proteins from this set of 5802 proteins were selected if they had a fold change of at 
least 1.5 up or down for either 1 or 5-day incubation with α-synuclein fibrils when 
compared to 0 days. There were 124 proteins with an increase and seven with a 
decrease after either 1 or 5-day incubation with α-synuclein fibrils. Paired t-tests were 
used to determine which of these peptides presented significant fold changes. There 
was a total of 11 proteins that had a significant fold change after 1-day or 5-day 
incubation (Table 4). Of these proteins, α-synuclein and collagen α-1(II) chain 
(COL2A1) were significantly increased after 1-day and 5-day incubation, whereas, 
microtubule-associated protein 4 (MAP4) was significantly decreased after both 
timepoints. The increase of α-synuclein was consistent with the addition of α-synuclein 
fibrils to the cells, thus acting as an internal control for the ability of the proteomics 
methodology to detect changes in protein level.                                                                                                                                                                            
FIGURE 24. Confirmation of protein present in whole cell lysate samples. Samples were produced 
from lysed SH-SY5Y GFP-α-synuclein cells after incubation with 1 µM Alexa Fluor 594-labelled α-
synuclein fibrils (monomer equivalent concentration) for 0, 1 or 5 days. Proteins were separated on a tris-
tricine gel (30% (w/v) acrylamide), with each lane containing 0.5 mg/mL of protein, followed by overnight 
staining with PageBlue Protein Staining Solution (Thermo Scientific). The molecular weight of the protein 





PANTHER 16.0 was used to conduct gene ontology (GO) enrichment analysis for the 
11 proteins that presented significant fold changes after incubation with Alexa Fluor 
594-labelled α-synuclein fibrils [159]. GO hierarchically classifies genes into terms to 
describe the complexity of biological systems. The terms are grouped into three 
categories: biological process, molecular function and cellular component providing an 
indication as to how each of the terms relates to one another [160, 161]. GO 
enrichment analysis finds which GO terms are over-represented for the set of genes 
being analysed in comparison to a reference list of the organism’s whole genome. For 
this project, the GO enrichment analysis applied the Fisher’s exact test to the genes of 
the 11 significant proteins against the H. sapiens genome (Table 5), [159]. The GO 
enrichment analysis was also used to identify reactome pathways that the list of genes 
belonged to (Table 6 and 7), [162].  
The only enriched biological process was collagen fibril organisation for collagen α-1(I) 
chain (COL1A1), collagen α-2(I) chain (COL1A2) and COL2A1, with several cellular 
components related to collagen fibrils and trimerization. The cellular components: 
supramolecular fibre and supramolecular polymer were enriched for the three collagen 
proteins as well as α-synuclein (SNCA) and MAP4. 
Several pathways were enriched for the proteins with significant fold change after 
incubation with α-synuclein fibrils. The first of these was integrin interactions for 
COL1A1, COL1A2 and COL2A1. The collagen proteins associate in trimers which then 
form fibres localised in the extracellular matrix, it is there where they interact with 
integrin proteins [162]. MET activation of PTK2 signalling was enriched for COL1A1, 










α-synuclein NACP 1.872 0.0180 3.306 0.0031 
Collagen α-1(II) chain COL2A1 1.518 0.0020 1.661 0.0279 
Collagen α-1(I) chain COL1A1 6.062 0.0297 --- --- 
Collagen α-2(I) chain COL1A2 2.847 0.0373 --- --- 
Microtubule-associated 
protein 4 
MAP4 0.617 0.0123 0.578 0.0110 
RNA polymerase-associated 
protein RTF1 homolog 
RTF1 0.543 0.0017 --- --- 
Non-specific serine/threonine 
protein kinase 
SIK3 --- --- 1.917 0.0244 
Skin-specific protein 32 XP32 --- --- 2.628 0.0296 
Protein tweety homolog 3 TTYH3 --- --- 1.861 0.0463 
Alpha-mannosidase 2 MAN2A1 --- --- 1.557 0.0157 
Coiled-coil domain-
containing protein 9B 
CCDC9B --- --- 1.551 0.0081 
 
TABLE 4. Proteins that present a significant fold change after SH-SY5Y GFP-α-synuclein cells were 





COL1A2 and COL2A1. This occurs during hepatocyte growth factor-induced cell 
motility. Phosphorylated MET interacts with a complex of collagen fibres and integrin 
which allows MET to activate the focal adhesion kinase PTK2 [163]. 
Platelet aggregation and GP1b-IX-V signalling were enriched for COL1A1 and 
COL1A2. During platelet aggregation the type I collagen fibres that consist of COL1A1 
and COL1A2 fibrils form a complex with von Willebrand factor (vWF) which then binds 
to the GP1b-IX-V receptor on the cell surface following injury [164].  
With the enrichment of terms and pathways involving COL1A1, COL1A2 and COL2A1 
and their significant fold change after incubation with α-synuclein, it is possible that 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































STRING analysis was used to observe interactions between the 11 proteins whose levels 
were significantly altered in the SH-SY5Y GFP-α-synuclein cells upon exposure to Alexa 
Fluor 594-labelled α-synuclein fibrils. STRING is a database of known and predicted 
protein-protein interactions including both physical and functional associations. It 
includes computational predictions, knowledge transfer between organisms and 
information collected in other databases. Protein-protein interactions are given scores 
which indicate the confidence of an association as opposed to the strength or specificity 
of the interaction [165]. STRING analysis did not present any direct association between 
α-synuclein (SNCA) and the other 10 proteins with significantly altered levels [165], (Fig. 
25). There is a cluster consisting of: COL2A1, COL1A2 and COL1A1. This was to be 
expected given their presence in the enriched pathways (Table 6 and 7).  
 
 
To explore the relationship between α-synuclein and the 10 other proteins with 
significantly altered levels, the STRING analysis was expanded to include proteins from 
the database that are associated either physically or functionally with the list of 11 
proteins whose levels altered significantly upon cell exposure to α-synuclein fibrils. The 
search was expanded to include proteins from the database to explore if there were any 
indirect associations of α-synuclein and the 10 other proteins with significantly altered 
levels via proteins from the database. Upon expanding the analysis, both COL1A2 and 
α-synuclein (SNCA) have associations with amyloid precursor protein (APP). However, 
the indirect association of COL1A2 and α-synuclein is predicted to be more likely via 
APP then Secreted Protein Acidic And Cysteine Rich (SPARC), rather than APP directly, 
as indicated in the figure by the intensity of the edges [165], (Fig. 26). α-synuclein is also 
CCDC9B 
XP32 
FIGURE 25. STRING protein association network for the proteins with significant fold change after 
SH-SY5Y GFP-α-synuclein cells were incubated with α-synuclein fibrils for 1 and 5 days. Number of 
nodes: 11, number of edges: 3 (vs 1 expected edges), PPI enrichment p-value 0.0157. Confidence score 
threshold was set at 0.4 (medium). Saturation of edges represents the confidence for a predicted 




indirectly associated with RNA Polymerase-Associated Protein RTF1 Homolog (RTF1) 




































































































































































































































































































































































































































































































































The 11 proteins whose levels were significantly altered in the SH-SY5Y GFP-α-synuclein 
cells upon exposure to Alexa Fluor 594-labelled α-synuclein fibrils were compared to lists 
from previous publications that focussed on α-synuclein interactions, α-synuclein fibril 
uptake, PD models and LBs in a variety of different model systems and sample types 
(Table 8). Of the 11 proteins with significant fold change after incubation with α-synuclein 
fibrils, five of them had not been identified in the examined proteomic studies, they were: 
COL2A1, RTF1, skin-specific protein 32 (XP32), alpha-mannosidase 2 (MAN2A1) and 
coiled-coil domain-containing protein 9B (CCDC9B). 
COL1A1 and COL1A2 were present in cortical LB inclusions from post-mortem human 
brain samples [166]. MAP4 was identified in pulldown experiments of α-synuclein 
interaction partners. The pulldown focussed on identifying partners of phosphorylated 
and non-phosphorylated α-synuclein. MAP4 was identified regardless of the 
phosphorylation state of α-synuclein [134]. Mahul-Mellier et al. (2020) incubated neurons 
with α-synuclein preformed fibrils in a LB formation model. Non-specific serine/threonine 
protein kinase (SIK3) and protein tweety homolog 3 (TTYH3) increased after 14 and 21 












































































































































































































































































































































































































































































































































































































































































































































































6. Discussion  
In this project, proteomics was used to study the effects of α-synuclein fibrils on the 
cellular proteome. It revealed that exposure of SH-SY5Y GFP-α-synuclein cells to α-
synuclein fibrils resulted in the altered expression of a number of cellular proteins. 
 
6.1. Proteins identified by proteomic analysis 
Several of the proteins that presented significant fold changes after incubation of SH-
SY5Y GFP-α-synuclein cells with Alexa Fluor 594-labelled α-synuclein fibrils have been 
identified in previous publications that utilised proteomics to study α-synuclein 
interactions, α-synuclein fibril uptake, PD models and LB formation (Table 8). Collagen 
α-1(I) chain (COL1A1) and collagen α-2(I) chain (COL1A2) were identified by Leverenz 
et al. (2007) in LBs extracted from neurons in the temporal cortex of dementia with LB 
(DLB) human brain samples [166]. However, homologs of COL1A1 and COL1A2 were 
not identified in the LB formation model developed by Mahul-Mellier et al. (2020) which 
involved incubating primary hippocampal mouse neurons with preformed α-synuclein 
fibrils [147]. With a significant increase of COL1A1 and COL1A2 seen in this project 
after 1-day incubation of SH-SY5Y GFP-α-synuclein cells with α-synuclein-fibrils and 
not after 5-days, it could be a transient response to the initial exposure. Therefore, it 
would be interesting to observe the levels of COL1A1 and COL1A2 with additional time 
points during the first 5 days, as well as observing their expression over the extended 
timepoints used by Mahul-Mellier et al. (2020), [147]. 
COL1A1 and COL1A2 form type 1 collagen fibrils. They are involved in the activation of 
PTK2 via the receptor tyrosine kinase MET. When complexed with integrins α2βI or 
α3β1, the type 1 collagen fibrils interact with active MET which in turn activates PTK2 





Lee et al. (2020) showed that PTK2 plays a role in neurotoxicity [168]. TAR DNA 
binding protein (TARDBP) proteinopathies occur in several neurodegenerative 
diseases including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD) 
[169, 170]. These proteinopathies cause impairment of the ubiquitin proteasome 
system (UPS) resulting in an accumulation of ubiquitinated proteins and a reduction in 
proteosome activity in neurons. Inhibition of PTK2 is reported to suppress the 
neurotoxicity induced by UPS impairment, allowing for alternative clearance of poly-
ubiquitinated proteins via the autophagy-lysosomal pathway (ALP) with the aid of 
sequestosome 1 [168].  
It would be interesting to investigate whether the initial increase in COL1A1 and 
COL1A2 observed in this project contributes to the neurotoxic role of PTK2 highlighted 
by Lee et al. (2020), [168]. As the activation of PTK2 by MET promotes cell motility 
[171], perhaps the initial increase in COL1A1 and COL1A2 is a way of bringing cells 
into proximity of each other to aid fibril transmission. This could be investigated using 
live cell tracking coupled with fluorescent labelling of the type 1 collagen fibrils and α-
synuclein fibrils.  
In this project, collagen α-1(II) chain (COL2A1) increased significantly after both 1 and 
5-days incubation with α-synuclein fibrils and was not identified in the previous 
proteomic studies focussed on α-synuclein interactions, α-synuclein fibril uptake, PD 
models and LB formation (Table 8). Type II collagen is an essential component of the 
FIGURE 27. Signal transduction via MET, a receptor tyrosine kinase. When MET interacts with the 
dimerised signalling molecule Hepatocyte Growth Factor (HGF), it allows MET to dimerise via its tyrosine 
kinase domain. MET autophosphorylates and becomes activated. By interacting with the 
collagen/integrinαβ complex, MET phosphorylates PTK2. Phosphorylation of PTK2 activates it, allowing 




cartilage extracellular matrix, maintaining the structure of connective tissues. It is 
important in bone formation, growth and joint function as well as playing roles in 
development and function of the eye and inner ear [172]. Type II collagen is implicated 
in a variety of disorders that present skeletal dysplasia, short stature as well as hearing 
and vision impairment [173]. Despite being significantly increased in this project, 
COL2A1 is not implicated in neurodegenerative disease and it has not been found as 
an interaction partner of α-synuclein.  
Changes in COL4A2 expression, which encodes collagen α-2(IV) chain (COL4A2), 
have also been observed in A30P α-synuclein transgenic mice [174]. COL4A2 was 
upregulated in both transgenic mice and dopaminergic neurons expressing A30P α-
synuclein [174]. COL4A2 is a major component of the basement membranes, an 
extracellular matrix structure that supports and influences cell signalling. Surprisingly, 
Paiva et al. (2018) found that α-synuclein did not bind to the DNA sequence of the 
COL4A2 gene, but it did bind to the promoter region for COL11A1 which was also 
highly upregulated in the A30P α-synuclein transgenic mice [174]. This suggests a 
potential role of α-synuclein in regulating expression of collagen-related genes and it 
could provide an explanation for the significant increases in COL1A1, COL1A2 and 
COL2A1 seen in this project.  
The induction of astrogliosis and glial scar formation are often present in central 
nervous system (CNS) injuries, especially spinal cord injury (SCI). Genome-wide 
expression analysis found that several genes encoding extracellular matrix proteins 
were elevated 14 days post-injury, with those encoding COL1A1 and COL1A2 being 
highly expressed [175]. The upregulation of collagen type I in the injured extracellular 
matrix environment is believed to contribute to astrogliosis and astrocytic scar 
formation. This was suggested to occur through signalling pathways involving integrins 
and N-cadherin [175]. Prevention of collagen type I signalling has been shown to 
potentially promote axonal regrowth and enhance functional recovery, reducing 
astrocytic scar formation [176]. If inhibition of collagen type I signalling promotes 
neuronal functionality, in combination with the presence of collagen type I in LBs and 
the ability of α-synuclein to alter collagen gene transcription, this points towards 
collagen proteins, especially type I, having a potential role in α-synuclein pathology. 
 
Microtubule-associated protein 4 (MAP4) was significantly decreased after GFP-α-
synuclein cells were incubated with α-synuclein fibrils for 1 and 5 days. MAP4 was also 
associated with monomeric α-synuclein in pulldown experiments of α-synuclein 
interaction partners, regardless of α-synuclein’s phosphorylation state [134].  




tubulin heterodimers. They play roles in a plethora of cellular processes including cell 
division, motility, development and intracellular organisation [177]. Distinct arrays of 
microtubules are responsible for their varying functions and the formation of such 
structures requires interaction with the microtubule-associated proteins (MAPs), [177]. 
MAPs are abundantly expressed in the nervous system; some have overlapping roles 
while others have opposing activities to organise the microtubule cytoskeletal 
architecture [178]. 
MAP4 is part of the MAP2/Tau family of MAP proteins which also includes tau and 
MAP2 [179]. The MAP2/Tau family plays roles in intracellular traffic control. Tau is 
important in the transport of synaptic vesicles and organelles with its overexpression 
shown to impede their transport [180]. MAP2 controls cargo sorting in differentiated 
neurons, distinguishing KIF1 and KIF5 dependent cargoes [181]. MAP4 has been 
shown to activate kinesin 2-driven transport in both Xenopus melanocytes and in vitro 
motility assays as well as inhibiting dynein motility [182, 183]. The MAP2/Tau family 
can also regulate microtubule dynamics through the control of microtubule-severing 
enzymes. MAP4 was shown to inhibit katanin-mediated microtubule severing, with tau, 
MAP2 and MAP4 all serving to protect microtubules against severing when katanin was 
overexpressed in mammalian cells [184, 185].  
Due to their involvement in a wide range of cellular processes, MAP proteins are 
implicated in a number of diseases. For example, mice lacking tau display age-onset 
neurodegeneration resulting in Parkinsonism and dementia [186]. In a cellular model of 
Prion disease, MAP2 was shown to be downregulated, which corresponded with low 
levels of tubulin [187]. MAP1B-deficient neurons exhibit presynaptic structural 
deficiencies and altered physiology, and mice with MAP1A gene mutations display 
Purkinje-cell degeneration [188, 189]. In all these cases it is not the pathological 
accumulation of the MAPs that is responsible for the disease but rather it is the 
deficiency that leads to the pathology. This highlights their importance in cellular 
homeostasis and that alterations in their interactions with microtubules is sufficient to 
induce pathological events that lead to neuronal disorders [177].  
With the level of MAP4 being significantly decreased in this project after 1 and 5-days 
incubation with α-synuclein fibrils, it will be interesting to determine how the reduction in 
MAP4 affects intracellular transport. As kinesin 2-driven transport is activated by MAP4 
[182, 183], the decrease in MAP4 levels could disrupt this transport causing 
accumulation of kinesin 2 cargo. Accumulation of cargo could then result in cell 
signalling being compromised and targeting of the cargo for clearance for example, by 
the UPS. If MAP4 levels could not be restored by the cells, or if other MAP proteins 




death. To determine whether the decrease in MAP4 does affect kinesin 2-driven 
transport, kinesin 2 and its cargo could be subjected to immunofluorescent staining in 
SH-SY5Y GFP-α-synuclein cells exposed to α-synuclein fibrils. This would provide a 
simple method for observing any disruption to kinesin 2 trafficking and any subsequent 
accumulation of cargo, as mislocalised cargo would be easily identifiable. Kinesin-2 
activity could be monitored using immunofluorescent staining coupled with live cell 
imaging whereby the time taken to load and deposit cargo could be monitored. If this 
was implicated, then immunofluorescent staining could also be used to determine 
whether kinesin 2 becomes targeted for degradation through observation of its 
localisation with certain organelles over time. These studies could also be applied to 
longer time points than those used in this project to determine the long-term 
implications of decreased MAP4 levels.   
 
Both Protein tweety homolog 3 (TTYH3) and non-specific serine/threonine protein 
kinase (SIK3) increased in SH-SY5Y GFP-α-synuclein cells after incubation with α-
synuclein fibrils for 5-days. TTYH3 and SIK3 also increased in the LB formation model 
by Mahul-Mellier et al. (2020) after incubation of primary hippocampal mouse neurons 
with α-synuclein preformed fibrils [147].  However, little is known about their function. 
TTYH3 is a chloride ion channel said to be present on the plasma membrane of cells in 
excitable tissue such as that of the brain and heart [190]. However, there are no 
publications at present which suggest involvement in disease or cellular signalling. 
SIK3 has been identified in large scale human kinome and phosphoproteome 
experiments via mass spectrometry, however, there are no details regarding its role in 
signalling pathways [191, 192]. Although the extended STRING analysis from this 
project did not show an association between either TTYH3 or SIK3 with α-synuclein, 
pulldowns for α-synuclein interaction partners could be used to confirm this 
experimentally.  
As well as COL2A1, four other proteins not identified by the examined proteomic 
studies (Table 8), showed significant fold changes in this project after incubation with α-
synuclein fibrils, these were: RNA Polymerase-Associated Protein RTF1 Homolog 
(RTF1), alpha-mannosidase 2 (MAN2A1), coiled-coil domain-containing protein 9B 
(CCDC9B) and skin-specific protein 32 (XP32), (Table 4). RTF1 decreased significantly 
after 1-day incubation with α-synuclein fibrils. It is a component of the PAF1 complex 
which functions during transcription by RNA polymerase II. The PAF1 complex is 
implicated in regulation of development and maintenance of embryonic stem cell 
pluripotency [193]. STRING analysis did not show α-synuclein to be associated with 




synuclein fibrils alters RTF1 gene expression as opposed to direct interaction. 
MAN2A1, CCDC9B and XP32 all increased significantly after 5-days incubation with α-
synuclein fibrils. MAN2A1 localises to the Golgi and catalyses the final hydrolytic step 
in the maturation of complex N-glycans [194]. The function of XP32 and CCDC9B are 
not well understood with the only gene ontology term for CCDC9B being RNA binding 
(GO:0003723) and no data available for XP32.  
 
6.2. Limitations and development of the model system 
The SH-SY5Y GFP-α-synuclein cell line is a simple experimental system. The ability to 
overexpress GFP-α-synuclein allows for easy identification of α-synuclein cellular 
localisation and inclusion formation as well as easy observation of the cellular effects α-
synuclein has on neuronal protein expression. However, because SH-SY5Y is a 
neuroblastoma derived cell line it may not fully replicate the full repertoire of neuronal 
responses to amyloid fibrils, therefore, the use of primary neurons would be beneficial 
to confirm the results of this project. Primary neurons from mice or neurons derived 
from human induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs) 
may represent better model systems. It may also be suitable to observe the effects of 
α-synuclein fibrils in a model system that replicates the environment of the human 
brain. Glial cells make up a large portion of the cell population within the brain and they 
interact with neurons in a variety of processes such as the promotion of tissue repair 
and regulation of ion and neurotransmitter concentrations around synapses [195, 196]. 
There may be responses of neurons to α-synuclein fibril exposure in the context of 
brain tissue that occur in the early timepoints of LB formation due to their proximity with 
glial cells. These observations cannot be identified in isolated cell systems and could 
be crucial for further understanding the contribution of α-synuclein to the pathogenesis 
of LBs in synucleinopathies such as PD. 
Further to the work in this project, transcriptomics could be used to observe changes in 
gene expression that occur due to exposure to α-synuclein fibrils. This would be useful 
as most of the proteins whose levels were significantly altered in this project have not 
been shown to associate with α-synuclein, therefore this could provide an answer for 
how their levels changed. This could occur via α-synuclein binding to the promoter 
regions of the genes expressing these proteins, as discussed earlier for the collagen 
proteins, or through interaction with transcription factors. Pulldown assays could be 
used alongside transcriptomics to identify α-synuclein interaction partners to explain 





It would also be interesting to investigate whether α-synuclein fibril polymorphs have 
different effects on the SH-SY5Y GFP-α-synuclein cell line when compared to those 
studied herein, particularly whether the difference in structures between the 
polymorphs elicit different cellular responses. Also, the fibrils used for this project were 
produced in vitro, therefore, it would be beneficial to observe the effects of ex vivo 
fibrils from human brain to test whether they replicate the cellular effects shown in this 
work.  
 
7. Conclusion  
By performing viability and seeding assays it has been shown that the SH-SY5Y GFP-
α-synuclein cell line is a suitable experimental model to study the cellular effect of 
amyloid fibrils. α-synuclein fibrils are not toxic to this cell line and they can successfully 
seed intracellular GFP-α-synuclein in this model. Proteomics has identified several 
proteins from this experimental model that may play roles in the early stages of 
degeneration of neurons in synucleinopathies. Some of the proteins whose levels were 
significantly altered after exposure to α-synuclein fibrils have been identified in other 
proteomic studies focussed on α-synuclein interactions, α-synuclein fibril uptake, PD 
models and LB formation. Understanding the role that these proteins play during typical 
cellular function and under pathological conditions will help provide new insights into 
the early stages of cellular dysfunction that result in the formation of LBs and the 
progression of synucleinopathies such as PD. 
 
8. Methods 
All reagents used were from Sigma unless otherwise stated. 
 
8.1. Preparation of fibril samples 
Fibrils for this project were prepared and provided by Michael Davies of the Hewitt 
research group. 500 µM recombinant monomeric α-synuclein was incubated for 3 days 
in PBS at 42°C with the addition of 5% Alexa Fluor 594-labelled monomer and 
constantly agitated by a magnetic stirrer bar (1500 rpm). The resultant fibrils averaged 
50nm in length [197]. 
 
8.2. Cell culture 
The SH-SY5Y GFP-α-synuclein cell line was derived from the SH-SY5Y neuroblastoma 




were cultured in Dulbecco’s modified Eagle medium supplemented with 10% fetal 
bovine serum, 5% Penicillin-Streptomycin, 5% GlutaMAX (Thermo Scientific) at 37°C in 
5% CO2.  
 
8.3. Cell viability assays 
For all viability assays, SH-SY5Y GFP-α-synuclein cells were plated out at 40,000 cells 
per well in 96-well CytoOne plates (Star Lab) and incubated for 24 hr at 37°C in 5% 
CO2. The medium was replaced, and the cells were incubated for a further 24 hr in the 
presence or absence of Alexa Fluor 594-labelled α-synuclein fibrils (1 µM final 
monomer equivalent concentration) or equivalent volume of PBS, at 37°C and in 5% 
CO2. Prior to the viability assays, lysis buffer provided in the Pierce LDH Cytotoxicity 
assay kit (Thermo Scientific) was added to a portion of untreated cells, these cells 
served as a background reading against which sample cells were compared. All 
viability assays were conducted in triplicate with three replicates for each treatment. 
Results of each viability assay were normalised against control cells incubated with 
PBS and presented as means for each treatment (mean ± 1 S.E.M). GraphPad Prism 9 
was used for comparison of treatments using Welch’s ANOVA or Kruskal Wallis, 
followed by Dunnett’s T3 multiple comparison or Dunn’s multiple comparison tests 
respectively with differences considered significant at p<0.05 (GraphPad Prism version 
9.0.1 for Windows, GraphPad Software, San Diego, California USA, 
www.graphpad.com).  
All viability assays were carried out with triplicate samples and three independent 
experimental repeats. Results were normalized using the signal for untreated cells 
incubated with PBS as 100% viability. 
 
8.3.1. Adenosine Triphosphate (ATP) assay 
The ATP assay was conducted in accordance with the protocol outlined in the ATPlite 
assay kit (PerkinElmer). Briefly, after incubation with fibrils, mammalian cell lysis 
solution was added to the cells for 5 minutes followed by ATP substrate solution for 5 
minutes, both these incubation stages occurred at room temperature on an orbital 
shaker at 700 rpm. Cells were dark adapted for 10 minutes at room temperature. The 






8.3.2. Lactate Dehydrogenase (LDH) assay 
The LDH assay was conducted in accordance with the protocol outlined in the Pierce 
LDH Cytotoxicity assay kit (Thermo Scientific). Briefly, after incubation with fibrils, 
reaction mixture was added to media from each cell sample and incubated for 30 
minutes at room temperature. Stop solution was added and the absorbance of each 
sample was read at 485/620 nm on an OPTIMA plate reader (BMG Labtech).  
 
8.3.3. 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay 
After incubation with fibrils, the medium was replaced, and cells were incubated for 3 hr 
with MTT (5 mg/mL). The medium was discarded, and the resulting formazan crystals 
were resuspended in dimethyl sulfoxide (DMSO) and incubated at 37°C, in 5% CO2 for 
30 minutes. The absorbance was measured at 570 nm on an OPTIMA plate reader 
(BMG Labtech).  
 
8.4. Analysis of fibril uptake 
Cells were plated out at 100,000 cells/mL in 6-well CytoOne plates (Star Lab) and 
incubated for 24 hr at 37°C in 5% CO2. Media was replaced and cells were incubated 
in the presence or absence of Alexa Fluor 594-labelled α-synuclein fibrils (1 µM 
monomer equivalent concentration in PBS) or equivalent volume of PBS, for 24 hr and 
5 days. After incubation, cells were subjected to live cell imaging. Cell media was 
replaced with imaging media (Dulbecco’s modified Eagle medium; phenol red free, 
supplemented with 10% (v/v) fetal bovine serum, 5% (v/v) Penicillin-Streptomycin, 5% 
(v/v) GlutaMAX (Thermo Scientific)). LysoTracker Deep Red (0.05 µM, Thermo 
Scientific) and Hoechst (5µg/mL) were added to cells 30 minutes prior to imaging. Cells 
were imaged using the Zeiss LSM700 confocal microscope with a 40X objective and 
analysed using ZEN software. Images were arranged and analysed using ImageJ 
[198].  
 
8.5. Analysis of seeding of GFP-α-synuclein aggregation 
Cells were plated out at 100,000 cells/mL in 6-well CytoOne plates (Star Lab) and 
incubated for 24 hr at 37°C in 5% CO2. Media was replaced and cells were incubated 
in the presence or absence of Alexa Fluor 594-labelled α-synuclein fibrils (1µM 
monomer equivalent concentration in PBS) or equivalent volume of PBS, for 5 days. 
Cells were permeabilized with 0.2% saponin and fixed with 4% formaldehyde. 




added to cells 30 minutes before imaging. Cells were imaged using the Zeiss LSM700 
confocal microscope with a 40X objective and analysed using ZEN software. Images 
were arranged and analysed using ImageJ [198]. 
 
8.6. Cell lysate preparation from cells incubated with α-synuclein fibrils for proteomic 
analysis 
Cells were plated out at 100,000 cells/mL in 6-well CytoOne plates (Star Lab) and 
incubated for 24 hr at 37°C in 5% CO2. Media was replaced and cells were incubated 
in the presence or absence of Alexa Fluor 594-labelled α-synuclein fibrils (1 µM 
monomer equivalent concentration in PBS) or equivalent volume of PBS, for 24 hr and 
5 days. There were three wells for each condition (0, 1 and 5-day incubation with 
fibrils). Cells were incubated for a total of 5 days with fibrils added at 1 or 5 days prior 
to collection. After incubation, media was removed, cells were washed with PBS and 
scraped from the plates, there was 1x106 cells/mL at the point of collection. Cells were 
spun down in PBS at 300 rcf in a bench top centrifuge for 5 minutes. Supernatant was 
discarded and lysis buffer (1% Triton X-100 in PBS with protease inhibitors (Pierce 
protease inhibitor mini tablets EDTA-free, Thermo Scientific)), was added to each cell 
sample. Cell lysates were spun down at 2000 rcf in a bench top centrifuge for 5 
minutes and the supernatant was retained. Samples were then frozen at -18°C until 
use.  
  
8.7. Assay of Protein concentration in cell lysates 
A BCA (Bicinchoninic acid) assay was conducted to quantify the protein concentration 
in each cell lysate sample. The principle of this assay is that proteins can reduce Cu2+ 
to Cu+ resulting in a colour change from light blue to purple that is proportional to the 
protein concentration of the solution [199]. Using the Pierce BCA Protein Assay kit 
(Thermo Scientific), samples were incubated with the assay solution for 45 minutes at 
37°C. Absorbance of each sample was measured at 562 nm on a NanoDrop 2000 
Spectrophotometer. The absorbances were compared to those of a standard curve to 
obtain the concentration for each sample analysed. For each timepoint, samples with a 
protein concentration of 2 mg/mL or higher were selected for further analysis. 
 
8.7.1. SDS-PAGE of cell lysates 
Whole lysate samples (0.5 mg/mL) were added to SDS sample buffer (0.0625 M Tris 
pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol, 0.1 M DTT, 0.01% (w/v) bromophenol blue) 




then separated on a tris-tricine gel (30% (w/v) acrylamide: 0.8% (w/v) bis-acrylamide) 
for 30 minutes at 60V followed by 90 minutes at 120V. The gel was then stained in 
PageBlue Protein Staining Solution (Thermo Scientific) at room temperature overnight 
on a rocker and then imaged using a Bio Rad ChemiDoc XRS+ gel imager.  
 
8.8. Proteomic analysis 
Proteomic analysis was conducted by Dr Kate Heesom and her team at the University 
of Bristol Proteomics Facility, as outlined below in the description provided by Dr 
Heesom. 
 
8.8.1. TMT Labelling, and High pH reversed-phase chromatography 
Aliquots of 50 µg of each sample were digested with trypsin (2.5 µg trypsin per 100 µg 
protein; 37°C, overnight), labelled with Tandem Mass Tag (TMT) 10plex reagents 
according to the manufacturer’s protocol (Thermo Scientific) and the labelled samples 
pooled. 
The pooled sample was desalted using a SepPak cartridge according to the 
manufacturer’s instructions (Waters, USA). Eluate from the SepPak cartridge was 
evaporated to dryness and resuspended in buffer A (20 mM ammonium hydroxide, pH 
10) prior to fractionation by high pH reversed-phase chromatography using an Ultimate 
3000 liquid chromatography system (Thermo Scientific).  In brief, the sample was 
loaded onto an XBridge BEH C18 Column (130Å, 3.5 µm, 2.1 mm X 150 mm, Waters, 
UK) in buffer A and peptides eluted with an increasing gradient of buffer B (20 mM 
Ammonium Hydroxide in acetonitrile, pH 10) from 0-95% over 60 minutes.  The 
resulting fractions (15 in total) were evaporated to dryness and resuspended in 1% 
formic acid prior to analysis by nano-LC MSMS using an Orbitrap Fusion Lumos mass 
spectrometer (Thermo Scientific). 
 
8.8.2. Nano-LC Mass Spectrometry 
High pH RP fractions were further fractionated using an Ultimate 3000 nano-LC system 
in line with an Orbitrap Fusion Lumos mass spectrometer (Thermo Scientific).  In brief, 
peptides in 1% (v/v) formic acid were injected onto an Acclaim PepMap C18 nano-trap 
column (Thermo Scientific). After washing with 0.5% (v/v) acetonitrile 0.1% (v/v) formic 
acid peptides were resolved on a 250 mm × 75 μm Acclaim PepMap C18 reverse 
phase analytical column (Thermo Scientific) over a 150 min organic gradient, using 7 




58 min, 32-40% B over 5 min, 40-90% B over 1 min, held at 90% B for 6 min and then 
reduced to 1% B over 1min) with a flow rate of 300 nL/min.  Solvent A was 0.1% formic 
acid and Solvent B was aqueous 80% acetonitrile in 0.1% formic acid.  Peptides were 
ionized by nano-electrospray ionization at 2.0kV using a stainless-steel emitter with an 
internal diameter of 30 μm (Thermo Scientific) and a capillary temperature of 300°C.  
All spectra were acquired using an Orbitrap Fusion Lumos mass spectrometer 
controlled by Xcalibur 3.0 software (Thermo Scientific) and operated in data-dependent 
acquisition mode using an SPS-MS3 workflow.  FTMS1 spectra were collected at a 
resolution of 120,000, with an automatic gain control (AGC) target of 200,000 and a 
max injection time of 50 ms. Precursors were filtered with an intensity threshold of 
5000, according to charge state (to include charge states 2-7) and with monoisotopic 
peak determination set to Peptide. Previously interrogated precursors were excluded 
using a dynamic window (60s +/-10 ppm). The MS2 precursors were isolated with a 
quadrupole isolation window of 0.7 m/z. ITMS2 spectra were collected with an AGC 
target of 10,000, max injection time of 70 ms and CID collision energy of 35%. 
For FTMS3 analysis, the Orbitrap was operated at 50,000 resolution with an AGC 
target of 50,000 and a max injection time of 105 ms.  Precursors were fragmented by 
high energy collision dissociation (HCD) at a normalised collision energy of 60% to 
ensure maximal TMT reporter ion yield. Synchronous Precursor Selection (SPS) was 
enabled to include up to 10 MS2 fragment ions in the FTMS3 scan. 
 
8.8.3. Data Analysis 
The raw data files were processed and quantified using Proteome Discoverer software 
v2.1 (Thermo Scientific) and searched against the UniProt Human database 
(downloaded August 2020: 167789 entries) using the SEQUEST algorithm.  Peptide 
precursor mass tolerance was set at 10 ppm, and MS/MS tolerance was set at 0.6 Da.  
Search criteria included oxidation of methionine (+15.995 Da), acetylation of the protein 
N-terminus (+42.011 Da) and Methionine loss plus acetylation of the protein N-
terminus (-89.03 Da) as variable modifications and carbamidomethylation of cysteine 
(+57.021 Da) and the addition of the TMT mass tag (+229.163 Da) to peptide N-termini 
and lysine as fixed modifications. Searches were performed with full tryptic digestion 
and a maximum of 2 missed cleavages were allowed. The reverse database search 
option was enabled and all data was filtered to satisfy false discovery rate (FDR) of 5%.    
 




Proteins were filtered out if; they were identified as contaminants (serum, keratin, not of 
human origin), they had less than two unique peptides or they had a fold change up or 
down of less than 1.5. Significant hits were determined by paired t-tests performed on 
the normalised data sets that showed a fold change up or down of 1.5, with p-values 
<0.05, using GraphPad Prism 9 (GraphPad Prism version 9.0.1 for Windows, 
GraphPad Software, San Diego, California USA, www.graphpad.com). 
 
8.10. Gene ontology and pathway analysis  
Statistical overrepresentation tests for the proteins that presented significant fold 
changes were conducted using the PANTHER Gene Ontology (GO) to apply a Fisher’s 
exact test with false discovery rate correction using H. sapiens as the reference 
species [159-161]. Molecular function, biological process and cellular component GO 
terms were examined for enrichment. Enrichment of pathways was also conducted 
through application of the same test using PANTHER GO.  
 
8.11. STRING protein association networks  
An interactome was constructed using STRING for the proteins with significant fold 
changes [165]. This was also expanded to include proteins from the STRING database 
that are associated with the list of significant proteins. The interactome was constructed 
using default settings, the confidence score was set to medium (0.4) with network 
edges showing the confidence of an interaction.  
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